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ABSTRACT OF DISSERTATION

HETEROGENEITY IN PLATELET EXOCYTOSIS
Platelet exocytosis is essential for hemostasis and for many of its sequelae. Platelets
release numerous bioactive molecules stored in their granules enabling them to exert a
wide range of effects on the vascular microenvironment. Are these granule cargo
released thematically in a context‐specific pattern or via a stochastic, kinetically‐
controlled process? My work describes platelet exocytosis using a systematic
examination of platelet secretion kinetics. Platelets were stimulated for increasing times
with different agonists (i.e. thrombin, PAR1‐agonist, PAR4‐agonist, and convulxin) and
micro‐ELISA arrays were used to quantify the release of 28 distinct α‐granule cargo
molecules. Agonist potency directly correlated with the speed and extent of release.
PAR4‐agonist induced slower release of fewer molecules while thrombin rapidly induced
the greatest release. Cargo with opposing actions (e.g. pro‐ and anti‐angiogenic) had
similar release profiles, suggesting limited thematic response to specific agonists. From
the release time‐course data, rate constants were calculated and used to probe for
underlying patterns. Probability density function and operator variance analyses were
consistent with three classes of release events, differing in their rates. The distribution of
cargo into these three classes was heterogeneous suggesting that platelet secretion is a
stochastic process potentially controlled by several factors such as cargo solubility,
granule shape, and/or granule‐plasma membrane fusion routes.
Sphingosine 1 phosphate (S1P) is a bioactive lipid that is stored in platelets. S1P is
essential for embryonic development, vascular integrity, and inflammation. Platelets are
an abundant source of S1P due to the absence of the enzymes that degrade it. Platelets
release S1P upon stimulation. My work attempts to determine how this bioactive lipid is
released from platelets. Washed platelets were stimulated with agonists for defined
periods of time and the supernatant and pellet fractions were separated by
centrifugation. Lipids were separated by liquid phase extraction and S1P was quantified
with a triple quadrapole mass spectrometer. A carrier molecule (BSA) is

required to detect release of S1P. Further, there is a dose‐dependent increase in total
S1P with increasing BSA. S1P release shows characteristics similar to other platelet
granule cargo e.g. platelet factor IV (PF4). Platelets from Unc13‐d Jinx mice and VAMP8‐/‐
mice, which are secretion‐deficient (dense granule, alpha granule and lysosome), were
utilized to understand the process of S1P release. S1P release was more affected in
Unc13‐d Jinx mice mirroring their dense granule secretion defect. Fluorescence
microscopy and sub‐cellular fractionation were used to examine localization of S1P in
platelets. S1P was observed to be enriched in a granule population. These studies
indicate the existence of two pools of S1P, a readily extractable agranular pool, sensitive
to BSA, and a granular pool that requires the secretion machinery for release. The
secretion machinery of platelets in addition to being involved in the release of normal
granule cargo is thus proved to be involved in the release of bioactive lipid molecules like
S1P.
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Chapter One
Introduction
Platelet overview
Platelets are natural band-aids circulating in the blood stream forming
hemostatic plug to stop bleeding upon vascular injury. They are 2.0-5.0 µm in diameter,
discoid, anucleate cells, at 150-400 × 109 per liter of whole blood, and surviving for 7-10
days. Electron-dense, dense granules, mostly peptide/protein rich alpha (α-) granules,
acid hydrolase-rich lysosomes, mitochondria and peroxisomes constitute the most
obvious organelles of platelets. A closed calcium rich network, dense tubular system
(DTS), invaginations of surface plasma membrane referred to as open canalicular system
(OCS), spectrin membrane cytoskeleton, actin cytoskeleton and peripheral microtubules
complete the structural entities of platelets (Figure. 1.1).
Accumulating evidence suggests that platelet functions are not restricted to
maintain hemostasis but are potentially important for inflammation, angiogenesis, and
maintenance of vascular permeability barrier (Ho-Tin-Noé et al., 2011). Recruitment of
fewer leukocytes to the inflamed organs in thrombocytopenic mice provided the first
mechanistic clue for the involvement of platelets in exacerbating inflammation (Devi et
al., 2010; Iannacone et al., 2008; Kuligowski et al., 2006). Regulation of tumor
angiogenesis by platelets is not surprising given the presence of both pro- and antiangiogenic factors in α-granules of platelets (Pinedo et al., 1998). The importance of
platelets in the maintenance of the vascular permeability barrier has been appreciated
for quite some time. Excessive leakage of radiolabelled albumin into the lungs and ears
of experimentally induced thrombocytopenic sheep (Lo et al., 1988) and rabbits
(Aursnes, 1974) provides evidence. Thrombocytopenic mice though do not show
spontaneous bleeding, but are more susceptible to vascular injury upon a localized
inflammatory stimulation (Goerge et al., 2008), further supporting a role for platelets as
vascular guardians (Ho-Tin-Noé et al., 2011). The pleiotropic functions of platelets are
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enabled by the secretion of hundreds of granule cargo molecules. Therefore,
understanding the mode of platelet secretion is important and significant.
The origin of platelets in circulation from megakaryocytes (MKs) and the overall
importance of platelet secretion in health and disease are highlighted in this chapter.
Platelet activation and the exocytotic machinery involved in platelet secretion are also
discussed. Additionally, this chapter also provides a summary of the present knowledge
on an important bioactive sphingolipid, S1P, which is stored in platelets and released
upon activation. The following commentary aims to synopsize the accruing roles of
platelet secretion.
Platelet biogenesis
Platelets are generated from MKs, which are 30-100 μm in diameter. These are
myeloid cells constituting less than 0.1% of total bone marrow cell population. MKs
undergo multiple rounds of mitosis without cell division; a process called endomitosis
which yields a multinucleate structure. The production of proteins and lipids is
proportional to their ploidy. During maturation, MKs migrate from the osteoblastic niche
to the vascular niche, a region proximal to the blood vessels of bone marrow cavity. Long
branching processes emanate from them, called pro-platelets and continue to mature in
the vasculature, eventually releasing individual platelets (Italiano et al., 1999).
Commitment of stem cells of megakaryocytic lineage, proliferation of the
progenitors, and final differentiation of MKs lead to the formation of platelets. The
megakaryocytic lineage arises from a common erythrocyte-MK progenitor derived from
a common myeloid progenitor in the bone marrow. The proliferating diploid MK
progenitors retain the capacity to duplicate DNA and form new cytoplasm, even though
they lose their ability to divide. MK maturation results in the formation of
megakaryoblast which ranges < 50-100 µm in cell size with a ploidy up to 128N (Tomer et
al., 1987; Tomer et al., 1988). With an increased nucleus to cytoplasm ratio these
structures do have all the organelles that are eventually seen in an individual platelet. As
the maturation process progresses, the polyploid nucleus acquires horse-shoe shape;
2

the cytoplasm, the demarcation membrane system expand and, the platelet organelles
increase in number. This is followed by the formation of pro-platelet projections that
finally result in 2000-5000 platelets per megakaryocyte (Deutsch and Tomer, 2006;
Italiano et al., 1999; Italiano and Shivdasani, 2003; Long, 1998).
Platelet activation
Platelets in circulation are maintained in a quiescent state by ‘passivators’ like
nitric oxide (NO) and prostaglandin I2 (PGI2). The premature activation of platelets is
prevented by intact endothelial cell monolayer which enables concealment of potential
platelet agonists like collagen and von Willebrand Factor (vWF). This is also achieved by
restricted accumulation of platelet stimulators like thrombin, ADP, thromboxane A2
(TxA2) and epinephrine (Brass, 2003). This is the first indication for platelet activation to
be a highly regulated process. To release their granular contents, platelets must be
activated. This occurs upon a vascular disturbance – injury, trauma, rupture of a plaque –
conditions that disrupt the vascular barrier resulting in local generation of thrombin
and/or exposure of collagen. The role played by NO and PGI2 in maintaining platelets in a
resting state in circulation is incumbent upon their ability to maintain high cyclic
nucleotide levels (cAMP or cGMP). The importance of PGI2 and NO is not only indicated
by PGI2 mimetics, acting as anti-platelet agents but also, by pro-thrombotic effects seen
in platelet specific PGI2 receptor null mice (Murata et al., 1997).
Platelet plug formation upon sensing a vascular injury occurs in three stages –
initiation, extension and perpetuation (Brass, 2003). Initiation phase includes the events
that culminate in the formation of focal point for the formation of platelet plug. Platelets
in circulation roll onto the ruptured vascular endothelial layer with exposed collagen.
The brake in the movement of platelets is potentiated by the interaction of GPVI
receptors present on platelet surface and collagen. This further leads to clustering of
GPVI receptors on the platelet surface ultimately leading to the mobilization of
intracellular calcium ([Ca2+]i) pools by the activation of PLCγ2. These events lead to the
successful formation of platelet monolayer. The extension phase relies on the presence
3

of platelet surface receptors which can bind to accumulating soluble agonists like
thrombin, ADP and TxA2. This facilitates recruitment and lodging of more platelets even
without direct contact with collagen. The interplatelet contacts in this phase are
mediated by the activated αIIbβ3. Perpetuation phase includes the events that maintain
the platelet plug preventing premature disaggregation.
Platelet activation is mediated by an array of cell surface receptors that sense
components produced at the site of vascular damage. Thrombin is a serine protease that
acts through PAR family receptors – PAR1/3/4 (Coughlin et al., 1992). The structure of
PARs is similar to other G-Protein-Coupled Receptors (GPCRs). Thrombin acts on PARs,
cleaving their N-termini, resulting in the exposure of a new N-terminus (SFLLRN for PAR1
and AYPGKF for PAR4) that acts as a tethered ligand (Chen et al., 1994; Vu et al., 1991).
This imparts a very high local concentration of ligand to bind to its receptor, and thus
thrombin is one of the potent platelet agonists. PAR1 is more immediately responsive to
thrombin at low concentrations, while PAR4 requires 10-100 fold more and is probably
responsible for the sustained activation of platelets (Covic et al., 2000; Shapiro et al.,
2000). The distribution of PARs on platelets varies across species. PAR1 and PAR4 are
expressed on human platelets (Kahn et al., 1999), while PAR3 and PAR4 are present on
mouse platelets. TxA2 through TP receptor and ADP through P2Y1 receptor – result in
increasing [Ca2+]i levels by activating Gq (Offermanns et al., 1997). ADP receptor P2Y12 and
epinephrine receptor α2A act through Gi2 (Yang et al., 2002) or Gz (Yang et al., 2000) to
inhibit adenylyl cyclase and, to activate PI3K and a Ras family member, RapI (Woulfe et
al., 2002). The importance of ADP-Gi2 coupled P2Y12 receptor is confirmed by the
phenotypes of the receptor knockout mice and the effectiveness of P2Y12 antagonists,
clopidogrel and ticlopidine (Foster et al., 2001; Hollopeter et al., 2001; Jantzen et al.,
2001). Irrespective of the receptor type, an activated platelet typically exhibits increase
in [Ca2+]i. This is an important trigger for platelet exocytosis. PARs and TP receptors by
coupling guanine nucleotide exchange factors with Rho, can also result in cytoskeletal
rearrangements responsible for platelet shape change and potentially secretion
(Offermanns et al., 1994).
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Platelet granules
Platelets broadly have three distinct types of granules – dense granules, αgranules and lysosomes. The salient features of each kind of granule are described here.
Dense granules
The dense granules are 250 nm, electron dense structures, first identified from
electron micrographs. There are typically three to eight dense granules per normal
human platelet (Israels et al., 1990; White, 1968). Their relatively acidic internal pH is
maintained by a H+ pumping ATPase located on the granule membrane (Carty et al.,
1981). Dense granules contain some P-selectin (Israels et al., 1992) which was initially
identified as α-granule protein (Stenberg et al., 1985), is essential for platelet-leukocyte
interaction. Similarly CD63 and LAMP2 originally identified as components of lysosomal
granule membrane are also present on the dense granule membrane (Metzelaar and
Nieuwenhuis, 1991, Silverstein, 1992 #42). The origin of various granule types from MKs
via multi vesicular bodies (MVBs) is therefore thought to be defined by the specific
distribution of contents.
These granules house a number of bioactive small molecules such as serotonin,
catecholamine, calcium, a non-metabolic pool of ADP and ATP and, pyrophosphate
(Holmsen and Weiss, 1979). Serotonin, though not synthesized by platelets, is taken up
from plasma and stored in dense granules where it is complexed with ATP or calcium (De
Clerck et al., 1984). Upon platelet activation serotonin is released from dense granules
and recruits more platelets to form an aggregate (Gerrard, 1988). Serotonin limits the
blood flow at the injury site by vasoconstriction, thus controlling the blood loss (De
Clerck et al., 1984). Calcium and polyphosphates stored in dense granules constitute 6070% of total calcium stored in platelets and are likely responsible for the electron density
seen in EM (Holmsen and Weiss, 1979; White, 1969). Hemansky-Pudlak syndrome (HPS)
and Chediak-Higashi syndrome (CHS) are genetic, dense granule storage pool disorders
(SPDs) which will be discussed further in the later section.
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Alpha granules
Alpha (α-) granules form the major granule population in platelets, ranging from
200-500 nm in size and 40-80 per platelet. Immunogold electron microscopy studies of
MKs suggest the development of α-granules and MVBs from budding vesicles off the
Golgi (Blair and Flaumenhaft, 2009; Heijnen et al., 1998; Jones, 1960). The studies by
Heijnen et al. have shown that there are two kinds of MVBs – type I, which have only
internal vesicles and type II, which have both internal vesicles and an electron dense
matrix (Blair and Flaumenhaft, 2009; Heijnen et al., 1998). MVBs form an intermediate
stage not only in the formation of α-granules (Heijnen et al., 1998) but also, dense
granules (Nishibori et al., 1993). This conclusion is based on the presence of
lysosomal/dense granule protein, CD63 also on MVBs (Nishibori et al., 1993).
There are hundreds of stored peptides and proteins (Qureshi et al., 2009) which
differ in their origin. The stored cargo can either be synthesized by the megakaryocyte
(e.g. vWF, platelet factor 4 (PF4) and β-thromboglobulin (β-TG)), de novo synthesized in
the platelet (e.g. IL8). Some α-granule cargo (e.g. fibrinogen and Factor V) are not made
by megakaryocytes but are thought to be endocytosed by circulating platelets (Louache
et al., 1991). They are then transported to α-granules (Harrison et al., 1989; Heijnen et
al., 1998). α-Granules contain hemostatic factors (e.g. Factor V, fibrinogen), angiogenic
factors (e.g. angiogenin, VEGF), anti-angiogenic factors (e.g. angiostatin, PF4), growth
factors (e.g. PDGF, SDF1α), proteases (e.g. MMP2, MMP9), necrosis factors (e.g. TNFα,
TNFβ) and other cytokines (Coppinger et al., 2004). Around 30 angiogenesis regulators
have been identified to be stored in platelets and are reported to be distributed to
different subclasses of α-granules depending on their biological function (Italiano et al.,
2008). Membrane proteins important for platelet function, like αIIbβ3 (Coller et al., 1991),
CD62P (P-selectin) and CD36 (Blair and Flaumenhaft, 2009) are present in α-granule
membranes. Patients with Gray Platelet Syndrome (GPS) lack recognizable α-granules
and presumably have a defect in their biosynthesis (Mori et al., 1984). GPS represents αgranule defect in platelets and is discussed in detail later.
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Lysosomes
Lysosomes constitute a sparse granule type in platelets (0-1 per platelet), and
they appear similar to α-granules in electron micrographs. Lysosomes store cathepsins,
carboxypeptidases, β-hexosaminidase, acid phosphatases, enzymes for hydrolyzing
various sugars and aryl sulfatases (McNicol and Israels, 1999; Thon and Italiano, 2012).
CD63 and LAMP2 serve as markers for lysosomes. Apart from platelets, secretory
lysosomes are also found in other hematopoietic cells like neutrophils, eosinophils, mast
cells, macrophages, and cytotoxic T lymphocytes (CTLs) (Andrews, 2000). Though the
exact function of lysosomes in platelets is not known, they are thought to be involved in
clot remodeling. CHS, Griscelli syndrome, and HPS are some of the autosomal recessive
disorders that exhibit impaired lysosomal biogenesis and exocytosis. These are further
described in the following section.
Platelet defects
The complications associated with platelet defects result in mild to severe
bleeding. They can be related to a defect in one of the receptors required for platelet
activation, or defective platelet biogenesis, or related to impaired cytoskeletal changes.
Some of such defects are discussed below.
Platelet biogenetic defects
These are the defects that result in the production of morphologically abnormal
platelets. Bernard-Soulier syndrome (BSS), MYH9 related disorders (MYH9RD) and GPS –
the

common

characteristic

associated

with

all

these

disorders

is

macrothrombocytopenia (decreased platelet number with increased platelet volume)
(Patel et al., 2005). BSS is autosomal dominant disorder with increased bleeding time
and impaired platelet aggregation. Deficiency or absence of glycoprotein GP-Ib/IX/V,
which is a receptor for vWF, is responsible for this disorder (Balduini et al., 2002). MYH9
related disorders have a defect in MYH9 gene which encodes for myosin heavy chain.
Though a defect in GP-Ib/IX/V has been reported, this disorder causes cytoskeletal
rearrangement anomalies upon platelet activation (Franke et al., 2005). GPS is another
7

autosomal dominant disorder which in addition to macrothrombocytopenia has a defect
in the production of α-granules. Granule contents leak from most of the organelles
during platelet development in MK leaving behind the empty α-granule vacuoles, which
are later on filled with cytoplasm of circulating platelets (Cramer et al., 1985; Stenberg et
al., 1998).
Dense granule SPDs
These disorders appear due to congenital deficiency of dense granules and
present as a moderate bleeding diathesis, manifested in a minority population as a more
severe life-threatening bleeding disorder. HPS (Hermansky and PUDLAK, 1959) and CHS
(Higashi, 1954), both autosomal recessive disorders characterized by hypopigmentation,
are representative of numerous dense granule SPDs. HPS patients have profound dense
granule deficiency and severe mucocutaneous bleeding and postoperative bleeding
necessitating repeated red cell and platelet transfusions (Gahl et al., 1998). HPS1,
AP3B1, HPS3-6, DTNBP1, BLOC1S3, BLOC1S6 genes (Masliah-Planchon et al., 2013) have
been identified to contribute to HPS (Di Pietro and Dell'Angelica, 2005; Gunay-Aygun et
al., 2004; Li et al., 2004). Many of these gene products make up the sorting complexes
that mediate the transfer of molecules to the granules. Histological analyses on CHS
patients reveal gigantic inclusion bodies in leukocytes, lysosomes and melanosomes in
melanocytes. While their platelets lack these abnormal granules, they also lack dense
granules (White and Gerrard, 1976).
α-Granule SPDs
GPS is an inherited α-granule formation disorder (Nurden and Nurden, 2007).
Patients with GPS exhibit moderate but, progressive thrombocytopenia (Nurden and
Nurden, 2011). The defective gene reported to be responsible for this disorder has been
localized to chromosome 3p (Fabbro et al., 2011). Moreover, mutation in Hzf, a zinc
finger transcription factor, results in the normal number of megakaryocytes and
platelets, but with reduced number of α-granules in platelets, mimicking GPS in Hzf

-/-

mice (Kimura et al., 2002). Two proteins have been identified to be important for α8

granule biogenesis: BEACH domain containing protein (NBEAL2 – deficient in GPS
patients) (Gunay-Aygun et al., 2011; Kahr et al., 2011) and Sec1/Munc18 protein
(VPS33B – deficient in arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome
patients) (Gissen et al., 2004; Lo et al., 2005). Though the mechanism of action of
NBEAL2 is unknown, VPS33B has been shown to facilitate membrane docking and fusion
during vesicle trafficking and α-granule formation (Lo et al., 2005). Loss of VPS33B, at
least in humans (but not in mice, unpublished communication), is responsible for a
defect in incorporation of endogenous and endocytosed proteins in α-granules of
platelets (Lo et al., 2005).
Platelet exocytosis machinery
Activated platelets release their granular contents into the extra-platelet space
by fusion of the granular membrane with the plasma membrane. This is facilitated by
the machinery that was initially identified in neurons (Sollner et al., 1993). It includes
vesicle-soluble N-ethylmaleimide sensitive fusion proteins (v-SNAREs), target-SNAREs (tSNAREs) and a number of regulatory proteins. The minimal requirement for fusion is the
pairing of cognate v- and heterodimeric/trimeric t-SNAREs to form a transmembrane
fusion complex (Weber et al., 1998). v-SNAREs (also known as Vesicle Associated
Membrane Proteins, VAMPs) are type II membrane proteins characterized by a 60-70
amino acid conserved SNARE motif and a transmembrane domain (Jahn and Südhof,
1999). t-SNAREs are of two types – syntaxin type and synaptosomal-associated protein
type (SNAP type). Syntaxins are type II integral membrane proteins with a characteristic
SNARE motif and an N-terminal regulatory domain (Dietrich et al., 2003). SNAP-23/25
family members contain two SNARE motifs and lack transmembrane domains. They are
anchored to the membrane by thioester-linked acyl groups (Dietrich et al., 2003).
Platelets (human and mouse) contain VAMP-2 (synaptobrevin), VAMP-3 (cellubrevin),
VAMP-5 (Burkhart et al., 2012), VAMP-7 (TI-VAMP), and VAMP-8 (endobrevin) (Bernstein
and Whiteheart, 1999; Polgár et al., 2002; Ren et al., 2007; Schraw et al., 2003). Human
platelets contain syntaxins - 1, 2, 4, 6, 7, 8, and 11 (Burkhart et al., 2012; Chen et al.,
2000a; Chen et al., 2000b; Coppinger et al., 2004; Lemons et al., 1997; Lemons et al.,
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2000), SNAP-23 (Flaumenhaft et al., 1999), SNAP-29 (Polgár et al., 2003), and SNAP-25
(Redondo et al., 2004). The representative SNAREs found in platelets leading to
exocytosis are represented in the Figure 1.2. The conserved SNARE motifs form a coiledcoil, four-helix bundle that is stabilized by the core hydrophobic interactions (Sutton et
al., 1998). The complex is sufficient to mediate membrane fusion in proteoliposomes
(Weber et al., 1998).
Tetanus toxin, a neurotoxin, is a heterodimeric zinc-dependent endopeptidase
specific for VAMP-1/2/3 (Schiavo et al., 2000). Initial studies of v-SNAREs in platelets
utilized this toxin and showed that α-granule release was inhibited (Flaumenhaft et al.,
1999). α-Granule secretion was also affected when antibody directed against the Nterminus of VAMP-3 was added to permeabilized platelets (Feng et al., 2002). The
results obtained in the previous studies did not correlate with the lack of secretion
defect in VAMP-3-/- mice (Schraw et al., 2003). Subsequent studies demonstrated that
VAMP-8 is the primary v-SNARE in mouse platelets (Ren et al., 2007). Secretion defects
were not seen in VAMP-3-/-, VAMP-2+/-/VAMP-3-/- and VAMP-2+/- platelets and were only
evident in VAMP-8-/- platelets, though not complete. The secretion defect is more
pronounced in α-granule and lysosomal release when compared to dense granule
release. Moreover, VAMP-8 independent release could be abolished by treating
permeabilized VAMP-8-/- platelets with tetanus toxin, alluding to the fact that VAMP-2
and -3 constitute a secondary, albeit less efficient, secretion machinery.
Among t-SNAREs, syntaxin-2 and SNAP-23 have been shown to be involved in the
release of all three granules using anti-SNARE antibodies in permeabilized platelets
(Chen et al., 2000a; Chen et al., 1994; Lemons et al., 2000). Syntaxin-4 was associated
with α-granule (Flaumenhaft et al., 1999) and lysosomal release (Chen et al., 2000a).
However, platelets from syntaxin-2 and -4, single or double knockout mice did not
display

any

release

defect.

The

platelets

from

Familial

Hemophagocytic

Lymphohistiocytosis type 4 (FHL4) patient, lacking syntaxin-11, had a severe secretion
defect. This demonstrates that syntaxin-11 is the essential syntaxin in platelets.
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Consistently, it was found to co-immunoprecipitate with VAMP-8 and SNAP-23 (Ye et al.,
2012). Taken together, it now appears that secretion from all three granules, dense,
alpha, and lysosomal, is mediated by the same core secretory machinery elements,
VAMP-8, SNAP-23, and syntaxin-11.
SNARE regulatory proteins dictate how, when and where SNARE complexes are
formed to drive the fusion process. Our lab has identified three regulatory proteins
Munc 13-4 (Ren et al., 2010), Munc 18b (Al Hawas et al., 2012) and tomosyn (Ye et al.,
unpublished) that play an important role in platelet secretion. Unc13d

Jinx

mice have a

deficiency in an important priming factor for secretion, Munc 13-4 and display a severe
dense granule secretion defect. α-Granule and lysosomal secretion was also severely
compromised. Rab27, which is thought to be required for both dense granule biogenesis
and exocytosis is also a Munc 13-4 binding protein (Shirakawa et al., 2005). Munc 18b
and tomosyn were initially identified due to their association with syntaxin-containing
complexes. Munc 18 proteins chaperone the syntaxins and are found associated with the
t-SNARE heterodimers and SNARE complexes (Carr and Rizo, 2010). The regulatory
proteins reported to be associated with syntaxins/SNARE machinery are Munc 18b and
tomosyn. Of the three isoforms of Munc 18 in platelets, Munc 18a/b/c, Munc 18b
appears to be critical and platelets from FHL5 patients (lacking Munc 18b) have a severe
platelet secretion defect (Al Hawas et al., 2012). Platelet secretion deficiency was
evident in all three granule types with Munc 18b deficiency. Tomosyn was thought to be
a negative regulator that binds to t-SNARE heterodimers and control v-SNARE binding.
Tomosyn was first identified in platelets in pull-down experiments using syntaxin/SNAP23 complex as bait. Tomosyn deficient mouse platelets have a more pronounced αgranule and lysosomal secretion defect and a severe bleeding diathesis (Ye et al.,
unpublished). At this stage there are other elements of secretory machinery that are yet
to be characterized. Platelets contain double C2 domain containing proteins (DOC2) and
synaptotagmin-like proteins (SLP) whose functions are yet to be fully defined.
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Platelet α-granule secretion-in health and disease
The more conventional role for platelets is in hemostasis. With more than 300
proteins known to constitute platelet secretome (Maynard et al., 2007) (proteins
thought to be released from α-granules), there is an increasing evidence that platelets
can play a number of roles in the vasculature.
Hemostasis
α-Granules house a number of adhesive proteins like fibrinogen and vWF which
mediate interplatelet and platelet-endothelial interactions. The adhesive receptors
responsible for platelet adhesion are found in α-granules viz., member of vWF receptor
complex, GP Ibα-IX-V (Berger et al., 1996), fibrinogen receptor, αIIbβ3 (Niiya et al., 1987)
and collagen receptor, GPVI (Suzuki et al., 2003). They are constitutively expressed on
the platelet surface. One-half to two-thirds of the total αIIbβ3 and one-third of the total
GPVI population reside in the α-granule membrane (Niiya et al., 1987; Nurden et al.,
2004; Suzuki et al., 2003). This population contributes to an increase in their surface
distribution upon stimulation. Coagulation factors like Factor V (Hayward et al., 1995), XI
(Hu et al., 1998) and XIII (Kiesselbach and Wagner, 1972) are stored in platelet αgranules. Factor V is endocytosed from the plasma while the other two are synthesized
in the megakaryocytes. Moreover, α-granules also store pro-thrombin (an inactive
precursor of thrombin) and a number of proteins required for intrinsic clotting cascade.
They have a number of protease inhibitors like plasminogen activation inhibitor-1 (PAI-1)
and α2-antiplasmin which inhibit plasmin mediated fibrinolysis (Rendu and BrohardBohn, 2001). All the enlisted entities stored in α-granules contribute to coagulation
cascade demonstrating the importance of α-granules in the maintenance of hemostasis
(Nurden and Nurden, 2007).
Inflammation
The receptors required for platelets to bind to other cell types such as
endothelial cells, leukocytes, monocytes and lymphocytes, and the storage and release
of inflammatory cytokines suggest a role for platelets in inflammation (May et al., 2008).
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Although the contribution of proteins like vWF and fibrinogen are important in
establishing the interplatelet and platelet-endothelial cross-bridges, it is difficult to
define the specific contribution of the platelet-derived pools. P-selectin participates in
establishing interactions between platelets and endothelial cells / monocytes /
lymphocytes / neutrophils (Larsen et al., 1989). Irrespective of whether platelets are
activated or not, platelets do adhere to intact activated endothelium, possibly through
the binding of endothelial cell surface expressed P-selectin to constitutively expressed Pselectin glycoprotein ligand-1 (PSGL-1) or GP-Ibα on the platelet surface (Frenette et al.,
1995; Massberg et al., 1998). The interactions are further strengthened upon platelet
activation through their reciprocal interactions as P-selectin from the α-granules is
exposed (Gawaz et al., 2005). Variety of platelet-foreign cell interactions induce a series
of pro-inflammatory consequences contributed by the release of several cytokines,
chemokines, proteases and coagulation factors (May et al., 2008).
There are several inflammatory factors stored and secreted from α-granules such
as PF4, GRO-α, SDF-1α, β-TG, RANTES, IL-8, IL-2, MIP-1α etc (Gleissner et al., 2008). PF4
is platelet-specific and abundant. It contributes to neutrophil adhesion and
degranulation, differentiation of monocytes and macrophages to foam cells, all actions
that exacerbate inflammation (Kasper et al., 2007; Kasper et al., 2004; Scheuerer et al.,
2000). Atherosclerosis, a chronic inflammatory disease exemplifies the role of platelets
in inflammation. It is characterized by the infiltration of immune cells into subendothelial layers of arterial wall, and platelets are reported to play a significant role in
both initiation and progression of the disease (Croce and Libby, 2007) by depositing
chemotactic mediators on the endothelial surface (von Hundelshausen and Weber,
2007). Many cytokines from α-granules such as RANTES, MCP-1, MIP-1α etc. are
detected in atherosclerotic plaques. Deficiency of P-selectin is associated with reduced
fatty streaks and plaque lesion size in mouse models of atherosclerosis like LDL receptor
-/-

and apolipoprotein E

-/-

(Collins et al., 2000; Dong et al., 2000). Platelet, and not

endothelial P-selectin is essential for neointimal layer formation upon vascular injury
and facilitates lesion development (Burger and Wagner, 2003).
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Angiogenesis
Though the involvement of platelets in angiogenesis has long been suspected
(Knighton et al., 1982), the mechanism of their role is only now being understood in
more detail (Kisucka et al., 2006). Both pro- and anti-angiogenic factors are present in
platelets. Growth factors are angiogenic activators that promote vessel wall
permeability, and recruit endothelial cells and fibroblasts. Relevant growth factors in αgranules of platelets include vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), and
hepatocyte growth factor (HGF) (Nurden et al., 2008; Rendu and Brohard-Bohn, 2001).
The highly elevated VEGF concentrations after hemostatic plug formation (Weltermann
et al., 1999), is an example of how the platelet pool of growth factors can have an
impact at the site of vascular injury. In vivo, VEGF is also accumulated in platelet thrombi
(Arisato et al., 2003). Platelet-derived VEGF, bFGF and PDGF have been shown to
promote the sprouting of new vascular vessels in an ex vivo rat aortic ring model (Brill et
al., 2004). Platelets being a store house for a variety of growth factors have significant
contribution in the process of wound healing. This has been shown in vitro through the
migration of osteogenic cells (Kark et al., 2006), proliferation of human tendon cells in
culture (Anitua et al., 2005) and healing of cutaneous wounds in diabetic rats (Moulin et
al., 1998).
α-Granules also store anti-angiogenic factors such as thrombospondin-1 (TSP-1),
which has been shown to inhibit endothelial cell proliferation and promote apoptosis
(Jimenez et al., 2000). TSP-1 deficient mice exhibit pro-angigogenic activity, which was
modulated by increased SDF-1α secretion from platelets (Jimenez et al., 2000). PF4 is not
only known for its inflammatory role but also acts as an anti-angiogenic cytokine that
probably affects the binding of VEGF and FGF to their receptors (Bikfalvi, 2004; Perollet
et al., 1998). Platelet α-granules contain other anti-angiogenic factors like angiostatin,
endostatin, tissue inhibitor of metalloproteinases-1 (TIMP-1), TIMP-4, etc. Fine balance
between platelet derived pro- and anti-angiogenic factors therefore becomes important
in determining the extent of angiogenesis at the site of platelet activation.
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Antimicrobial action
Platelets, though known for a very long time to accentuate microbial infections
because of their adhesion properties, they are now being categorized as agents for
arresting microbial action. Platelets interact directly with bacteria (Clawson CC, 1975),
virus (Bik et al., 1982; Zucker-Franklin et al., 1990), fungi (Maisch and Calderone, 1980)
and protozoa (McMorran et al., 2009). One of the more recent studies implying the
antimicrobial action of platelets demonstrated that platelets can bind to plasmodiainfected erythrocytes and mediate their destruction (McMorran et al., 2009). Several
CXCL proteins in α-granules have both anti-inflammatory and microbicidal properties
such as RANTES, connective tissue activation peptide 3 (CTAP3) and PF4 (Cole et al.,
2001; Tang et al., 2002; von Hundelshausen and Weber, 2007).
Platelet heterogeneity
The short life span and the continued production of platelets from MKs generate
inherent population heterogeneity. Platelet granule cargo molecules are generated in
MKs or are endocytosed from circulation. This raises the possibility of MK environment
determining the kind of granule cargo synthesized. This reasoning is bolstered by the
rapidity of newly reported moieties in platelets (Senis and García, 2012). With the
release of cargo molecules of opposing functions, platelets contribute significantly in
delineating the microenvironment of the injury site. With heterogeneous contents of
platelets dictating the redesign of the injured site, the pattern followed by the secretion
process becomes essential to understand.
The concept that the contents with opposing physiological functions are packed
in distinct granules in platelets and released selectively with distinct agonists,
revolutionalized the concept of platelet secretion (Italiano et al., 2008). Immunofluorescence and immuno-electron microscopy show distinct localizations for pro- and
anti-angiogenic factors (Italiano et al., 2008). Consistently, other studies have shown
that stimulating platelets with different agonists (i.e. PAR1- and PAR4-agonists) causes
differential release of certain cargo (Chatterjee et al., 2011; Italiano et al., 2008; Ma et
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al., 2005). This led to the proposal that platelet secretion is contextually thematic:
capable of releasing specific sets of cargo (e.g. pro- or anti-angiogenic factors) in
response to specific agonists (Folkman, 2007; Italiano et al., 2008). More recent studies
have suggested that cargo is spatially segregated into sub-regions of the same
membrane bound granules and that there is little co-localization of factors with like
functions (Kamykowski et al., 2011; Sehgal and Storrie, 2007). Though intriguing, it is
difficult to ascertain how platelets release their myriad cargo in response to the agonists
generated at the site of vascular damage. Addressing this question is significant since, if
there is heterogeneity in cargo packing and/or secretion, regulating the release of
specific α-granule

sub-populations may allow specific manipulation of the

microenvironment at an injury site without disturbing hemostasis. The platelets were
raised from a conservative view that establishes non-selectivity in the release process to
a more easily controllable system and an assertive solution in manipulating platelet
secretion in the present times. My work addresses the question “Are platelets smartbombs?” The ensemble of biochemical and mathematical analyses not only alluded to
heterogeneity in platelet secretion but also an associated pattern dependent on agonistpotency.
Bioactive lipids
Platelets are not only reservoirs for small molecules and proteinaceous
substances described above, but they also house a number of bioactive lipid molecules.
Bioactive lipids like diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3) (Nishizuka,
1992), eicosanoids (Serhan and Savill, 2005), multiple products of inositol phospholipid
metabolism (Hannun and Bell, 1989), lyso-phosphatidic acid (LPA) and platelet activating
factor (Hannun and Obeid, 2008) are of great physiological significance. In addition to
the compounds listed above, sphingolipids occupy a special place in biology. These are
major lipids in eukaryotic plasma membrane (Kihara et al., 2007). Originally thought to
be just structural components of cell membrane (Simons and Ikonen, 1997),
sphingolipids are recognized to be biologically active and key for both inter and intra
cellular signaling (Leclercq and Pitson, 2006). Many of the sphingolipid metabolites like
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ceramide, sphingosine and sphingosine-1-phosphate (S1P) have been identified as
bioactive lipids (Yatomi et al., 1997).
In early 20th century it was noted that the barrier function of endothelium during
organ reperfusion was controlled by platelets (Danielli, 1940). Later it was shown that
platelets, in addition to their role during organ reperfusion, are also required for
maintenance of normal vasculature (Aursnes, 1974; Lo et al., 1988). The protective role
of platelets was initially explained by an ‘adhesion theory’ in which, platelets
mechanically filled the gaps in endothelium (Danielli, 1940; Gimbrone et al., 1969). In
vitro studies have shown the existence of several molecules in platelets that reduce
vascular permeability like adenine nucleotides (Paty et al., 1992), serotonin (Shepro et
al., 1984), S1P (Schaphorst et al., 2003), LPA (Alexander et al., 1998). Platelets serve as
vascular guardians in developing blood vessels, lymphatics, and in the microvasculature
at the sites of inflammation and tumor formation by reducing leukocyte infiltration (HoTin-Noé et al., 2011).
Bioactive lipids as platelet signaling molecules
TxA2 is a highly potent intermediate in the conversion of arachidonic acid to
thromboxanes (Hamberg et al., 1974). It is an important inducer of platelet activation
and is known to recruit platelets to the site of vascular injury. LPA is generated on the
platelet surface (Eichholtz T, 1993) by autotaxin (Lysophospholipase D) (Umezu-Goto et
al., 2002). Generation and storage of S1P in platelets will be described in the following
sections in detail. All these bioactive lipid mediators are shown to play a role in
atherogenesis, tumor development and thrombogenesis.
Sphingolipid metabolism
Ceramide is the central metabolite in an intricate sphingolipid metabolic
pathway. It can either be synthesized de novo or can be a break-down product of
complex lipids like sphingomyelin. Condensation of serine and palmitoyl CoA by the
action of serine palmitoyl CoA transferase (SPT) results in the formation of 3-keto
dihydro sphingosine. Its subsequent reduction forms dihydrosphingosine (sphinganine)
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which upon acylation by ceramide synthase results in the formation of ceramide with
the intermediate dihydro ceramide (Bartke and Hannun, 2009; Mandon et al., 1992).
Ceramide is acted upon by ceramidase to form sphingosine (Mao and Obeid, 2008)
which upon phosphorylation by sphingosine kinase forms S1P (Hait et al., 2006; Kohama
et al., 1998). Being a central product of sphingolipid pathway, ceramide can also form
sphingomyelin by the addition of phosphocholine head group from phosphatidyl choline
(Tafesse et al., 2006) or phosphorylated to ceramide-1-phosphate (C1P) or glycosylated
to form glycosyl/galactosyl ceramide (Ichikawa and Hirabayashi, 1998). Each of these
metabolites via a hydrolytic pathway catalyzed by specific enzymes can be turned into
ceramide. As was mentioned above, sphingosine is phosphorylated to make S1P. This is
achieved by the action of one of the two isoforms of sphingosine kinase – 1 or 2 (Hait et
al., 2006). Once formed S1P can be degraded back into sphingosine by the action of S1P
phosphatase (Johnson et al., 2003) or irreversibly to ethanol amine phosphate and
hexadecenal by S1P lyase (Bandhuvula and Saba, 2007). A summary of sphingolipid
metabolism is represented in Figure 1.3.
Sphingosine-1-Phosphate (S1P)
S1P has roles in processes such as cell migration, maturation, differentiation,
vascular integrity and angiogenesis (Hla, 2004). This is facilitated by several S1P
receptors previously referred to as EDG (Endothelial Differentiation Gene family)
receptors. S1P receptors now form a new class and should not be confused with EDG
receptors which bind to lyso-phosphatidic acid (Chun et al., 2002). Expression of various
isoforms of S1P receptors (S1P1-5) on multiple cell types is responsible for the variety of
extracellular roles of S1P (Spiegel and Milstien, 2003). S1P1-3, 5 are absent, while S1P4
mRNA has been detected in platelets (Motohashi et al., 2000). The presence of S1P4 in
platelets might explain the induction of slight shape change of platelets incubated with
exogenous S1P (Yatomi et al., 1995). This response was inhibited by LPA treatment
(Yatomi et al., 1997). However, it is unclear whether S1P4 protein is expressed and
functional in platelets. One report did show diminished pro-platelet production by S1P4-/mice indicating the importance of it in MKs (Golfier et al., 2010).
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Apart from its extracellular roles, S1P is an important secondary messenger
playing a role in the release of Ca2+ stores and is thus implicated in regulation of Ca2+
homeostasis (Ghosh et al., 1990; Ghosh et al., 1994). S1P has been shown to be
associated more with high density lipoprotein (HDL) in blood and that it mediates antiatherogenic actions like cell survival, migration and inhibition of the adhesion molecule
expression through the S1P receptors present on the endothelial cells (Kihara et al.,
2007; Okajima, 2002). Along with this role, S1P is also involved in cell proliferation and
survival (Olivera and Spiegel, 1993). The concept of a sphingolipid rheostat, which
represents the dynamic balance between cellular S1P and sphingosine / ceramide, is
widely accepted (Spiegel and Milstien, 2002). In this model, the fate of a cell is
determined by the relative levels of sphingolipid metabolites (e.g. ceramide and
sphingosine are pro-apoptopic, S1P and C1P are anti-apoptopic (Chalfant and Spiegel,
2005; Cuvillier, 2002)).
S1P is abundant in plasma and the reservoirs are thought to be platelets (Yatomi
et al., 2001), erythrocytes (Pappu et al., 2007) and vascular endothelium (Venkataraman
et al., 2008). The source of S1P in the maintenance of vascular integrity is unknown. To
address this question, a mutant mouse model with minimal availability of the enzyme
required for S1P synthesis was made (Camerer et al., 2009). As was mentioned above,
synthesis of S1P from sphingosine requires SK1 and SK2 (Hait et al., 2006). To overcome
the embryonic lethality associated with complete loss of S1P synthesis (Mizugishi et al.,
2005), a mouse with one SK1 allele and one SK1 null allele in SK2 null background
carrying a myxovirus resistance 1–Cre was generated. These mice will be referred to as
plasma-S1P less mice from here on. Plasma-S1P less mice demonstrated the importance
of S1P in the maintenance of vascular integrity (Camerer et al., 2009). The aberration in
vascular integrity of plasma-S1P less mice was restored by erythrocytes, which are
responsible for bringing normal plasma-S1P levels back. Platelets and erythrocytes are
the hematopoietic reservoirs of S1P. The release of S1P from RBCs is constitutive (Hänel
et al., 2007) while platelets have been reported to release S1P only upon their
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stimulation (Yatomi et al., 1995). This points to a role for platelets in determining the
local concentrations of S1P and thus vascular integrity (Figure 1.4).
Transport of S1P
For signaling, availability of S1P is dependent upon its transport to the right
location. ABC transporters have been shown to play a role in the release of S1P from
various cell types.
ABCC1 exports S1P from mast cells (Mitra et al., 2006). An ABCA-like exporter is
thought to be involved in the release of S1P from platelets (Kobayashi et al., 2006).
ABCA1 mediates export in astrocytes (Sato et al., 2007). The effects of various ABC
transporter inhibitors led to these conclusions. However, it should be noted that
deletion of any of these transporters had no effect on plasma S1P levels (Kawahara et
al., 2009; Lee et al., 2007; Osborne et al., 2008).
S1P transport in astrocytes
Astrocytes are the star-shaped neural cells present in both brain and spinal cord
(abundant in brain). They help in the maintenance of the blood brain barrier and play an
important role in the formation of scar after a traumatic brain injury. Rat astrocytes
treated with retinoic acid and dibutyryl cAMP result in the formation of Apo E and HDLlike particles. This stimulated the release of accumulated S1P through ABCA1 transporter
in the presence of exogenous sphingosine (Sato et al., 2007). These events are
demonstrated treating the cells with general ABC transporter inhibitor, small interfering
RNAs specific to ABCA1 and through ABCA1-/- mice.
S1P transport in mast cells
S1P secretion from mast cells (both constitutive and Ag stimulated) was not
associated with degranulation or exocytosis but has been reported to occur through
ABCC1 transporters. ABCB1 and ABCC1 but not ABCC2 or ABCC3 are present on mast
cells but only ABCC1 has been shown to be involved in S1P secretion (Mitra et al., 2006).
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Transport of S1P analog, FTY720-P (Fingolimod)
S1P in plasma is known to regulate circulating lymphocytes through S1P1 (Hla et
al., 2008; Rosen and Goetzl, 2005). Similar to the conversion of sphingosine to S1P by the
action of SK, its structural analog FTY720 (Fingolimod; 2-amino-2-[2-(4-octyl
phenyl)ethyl]-1,3-propanediol) is converted to FTY720-P. FTY720-P binds to S1P1
(Brinkmann, 2007; Rosen and Goetzl, 2005), expressed on lymphocytes/endothelial cells
and acts as an immuno suppressive agent. Fingolimod has been approved in Russia and
was approved by US FDA at the end of 2010 for the use in treatment of multiple
sclerosis. The conversion of FTY720 to FTY720-P has been observed in platelets, but not
in erythrocytes. The reason for this inability of erythrocytes is the absence of the kinase
SK2 (Anada et al., 2007). ABC transporters that have been suggested to transport S1P in
different cell types, are incapable of transporting FTY720-P. However, it can be
transported by spns2 (Hisano et al., 2011). Moreover it is known that unlike S1P, FTY720P is released from platelets irrespective of stimulation. The following is a short
description of the identification of spns2 as a possible candidate for the transport of S1P.
The phenotype of the zebra fish model ‘Miles apart’ was cardiac bifidia (two
hearts) in the embryonic development and the gene that was affected here is S1P2. The
ko157 mutant was isolated using N-Ethyl-N-nitrosourea (ENU) screening in an attempt to
identify the regulators involved in the development of heart. The defect that was
observed in this mutant was cardiac bifidia. The defect seen in the ko157 mutant
coincided with the phenotype observed when the gene corresponding to spns2 is
defective. Injection of mRNA of spns2 in the ‘miles apart’ model, compensated for the
defect observed during the development of the heart. The same was also shown by
introducing the human version of spns2 in the zebra fish model of ‘miles apart’. This
could not be replaced by spns1 (both zebra fish and human).
Spns2 transporter
Though the S1P levels of plasma are always very high (µM) and S1P is bound to
HDL/albumin (Aoki et al., 2005; Argraves and Argraves, 2007; Christoffersen et al.,
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2011), there is high activity of S1P lyase in plasma. This is indicated by the degradation
of C17S1P with a half life of 15 min. Maintenance of S1P levels in plasma even with such
rapid and continuous degradation signifies the contribution of S1P from platelets,
erythrocytes and endothelial cells (Lee et al., 2007; Venkataraman et al., 2008; Yatomi et
al., 1997). This intensified the identification of residence of spns2. Spns2 deficient mice
are lymphocytopenic. The development of all organs including the heart was normal in
spns2 deficient mice suggesting its different physiological roles in zebra fish and mice.
The sequence identity of spns2 in zebra fish with human/mouse is 72% and that
between human and mouse is 95%. The plasma S1P levels when compared to wild type
are

reduced

by

60%

unaffecting

the

intracellular

levels

of

S1P

in

brain/lung/spleen/thymus. The release of S1P from platelets and erythrocytes is not
affected in spns2 deficient mice indicating that spns2 is not important for S1P transport
in these cell types. Spns2 expression proved to be essential for the release of S1P from
vascular endothelial cells (Hisano et al., 2012). One of the mammalian physiological S1P
transporter responsible for maintenance of plasma S1P levels is thus identified to be
spns2.
S1P in platelets
S1P is known to perform its action ubiquitously. Its pleiotropic functions are
attributed to its spatial and temporal availability. The plasma levels of S1P are
maintained by platelets, endothelial cells and erythrocytes. S1P is maintained at low
levels in most of the cell types through the action of S1P phosphatase or S1P lyase. S1P
is produced momentarily when required. Uniquely, platelets store abundant quantities
of S1P because they lack S1P lyase/S1P phosphatase. The rate of formation of S1P from
sphingosine and the absence of enzymes degrading S1P in platelets do contribute to its
high levels. The release of S1P from platelets is regulated but the mechanism is
unknown.
The present knowledge about the release of S1P from platelets is dependent on
the research that relies on the use of general ABC inhibitors. This was preceded by the
work on astrocytes and mast cells. Its importance during development is highlighted by
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the zebra fish ‘miles apart’ phenotype (Osborne et al., 2008). The significance of S1P in
the maintenance of vascular permeability barrier is exemplified by vascular leak in
plasma-S1P less mice (Camerer et al., 2009). S1P is able to exert its functions by binding
to variety of receptors expressed on various cell types. Platelet secretory contents are
known to modify vascular microenvironment upon injury. Identifying the mode of
release of S1P from platelets will aid in understanding the extent of platelet S1P
participation at the injury site.
Preamble to the thesis
With an established role in multiple disease states, the study of platelet secretion
becomes extremely relevant. The identification of the modes of platelet exocytosis
events will help to better identify the therapeutic targets for its regulation. Thematic
release of platelet granule cargo has been suggested (Italiano et al., 2008) which
revolutionized the platelet field. One of the major focuses of the thesis is to address the
question of platelet secretion heterogeneity. This was accomplished by looking at the
release kinetics of thirty different cargo molecules upon stimulation of platelets with
various agonists. Platelets form a circulatory reservoir of a bioactive lipid, S1P. The mode
of release and its localization in platelets is unclear. The utilization of platelet secretiondeficient mice helped to identify two different pools of S1P in platelets. This thesis
accentuates the importance of mode of platelet secretion, whether protein or lipid.
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Type of defect

Platelet

Name of the disorder

Description

Bernard-Soulier syndrome (BSS)

Deficiency or the absence of GP Ib/IX/V;
Macrothrombocytopenia.
Macrothrombocytopenia, abnormal cytoskeletal

MYH9 related disorders

rearrangements upon activation.

Biogenesis

Anomalies in chromosome 3p; Defective storage of

Gray Platelet syndrome (GPS)

proteins in α-granules, macrothrombocytopenia.

Deficiency in dense granules; Occulocutaneous albinism;

Hermansky Pudlak syndrome (HPS)

Decreased aggregation and secretion upon activation.

Granule
Genesis

Deficiency in dense granules; Decreased aggregation and

Chediak-Higashi syndrome (CHS)

secretion upon activation.

GPS

Empty α-granules

Quebec syndrome

Abnormal content of α-granules

(α2β1 collagen receptor, GPVI collagen

Receptor
associated

receptor,P2Y12 ADP receptor, TPα TxA2 receptor)
associated disorders

Mild bleeding disorders. Reduced response to their
corresponding agonists.

Table 1.1. List of some platelet disorders
A list of platelet defects categorized as described in the left column. Name of the
disorder is represented in the middle column while the right column includes description
of platelets in the corresponding disorder.
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Figure 1.1. Platelet morphology
A cartoon of a platelet highlighting the morphological entities labeled in pink, while
those in blue represent various granule populations of a platelet.
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Figure 1.2. Platelet secretion machinery
Major v- and t-SNAREs present in platelets are listed and the functionally relevant
SNAREs are highlighted in magenta, green and blue. Cognate v-SNARE (on vesicle) and tSNARE (on plasma membrane [PM]) and SNAP-23 constitute potential platelet fusion
machinery (1). Following docking of the vesicle (2), the membrane fusion proceeds
further (3). Vesicle and the plasma membrane fusion leads to the release of vesicle
contents to the exterior (4).
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Figure 1.3. Sphingolipid metabolism
The central molecule of sphingolipid metabolism is ceramide (CD). Serine and palimitoyl
CoA (SP) through the action of Serine Palmitoyl Transferase (SPT) form
dihydrosphingosine. This can be converted to CD by the action of CD synthase. CD can be
a breakdown product of sphingomyelin (SM) by the action of the enzyme
Sphingomyelinase (SMase). CD can be converted back to SM by the action of SM
synthase. CD can also be reversibly utilized for the formation of complex
glycosphingolipids as represented. Sphingosine (S) is formed from ceramide by the
action of CDase, which can be converted back to CD by CD synthase. Sphingosine further
forms sphingosine-1-phosphate (S1P) by the action of sphingosine kinase (SK) or
reversibly converted to Sphingosine by the action of S1P phosphatase (SPPase). S1P can
also be irreversibly converted to ethanol amine phosphate and hexadecenal by the
action of S1P lyase. The absence of S1PPase and S1P lyase enzymes in platelets is
highlighted by the pink crosses.
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Figure 1.4. S1P in circulation
The cartoon represents microvascular injury and the sources of S1P. Endothelial cells are
represented by the nucleated brown rectangular cells with smooth edges. Erythrocytes
and platelets are red and pink ellipses respectively. The yellow circle in platelets
represents a granule. S1P in circulation is bound to albumin or HDL and is represented
by a green hydrophilic head group and a black hydrophobic tail encapsulated in an
orange cup representative of albumin/HDL. Upon vascular injury (1), a series of reactions
involving the conversion of SM to S1P as represented in the gray box (2) go on in
endothelial cells. At the same time platelets are activated at the site of injury and the
fading green circle is representation of diminishing gradient (red arrow) of released S1P
from the platelets. The S1P from platelets/endothelial cells could be released via ABC
transporters (3) and binds to S1P receptors present on endothelial cells (4). This further
leads to intracellular signaling in endothelial cells (5) ultimately resulting in wound
healing.
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Chapter Two
Materials and Methods
Human platelet preparation
Fresh human platelets from male donors were isolated and adjusted to 1.2 x
109/mL. All the steps were performed at room temperature (RT). Blood was collected
into acid citrate dextrose (ACD) vacutainer tubes by a phlebotomist at UK clinic. After
pooling the collected blood into a falcon tube, samples were centrifuged at 250 × g for
about 20 min to separate red blood cells (RBCs) from platelet rich plasma (PRP) [Banked
human platelets are prepared from PRP obtained from the Kentucky Blood Center
(KBC)]. All the centrifugation steps were carried out at intermediate acceleration and
minimal deceleration. To label the dense granules, PRP was incubated with 0.4 µci/mL
[3H]-5-hydroxy tryptamine/[3H]-serotonin (PerkinElmer) for 45 min. Prostaglandin I2
(PGI2) (50 ng/mL, Sigma) was employed at each step to maintain the platelets in a
resting state during the centrifugation steps. The samples were then centrifuged at 140
× g for 13 min to eliminate residual RBCs. The PRP was carefully separated not
disturbing the leukocyte layer present at the interface of RBCs and PRP. Separated PRP
was then centrifuged at 1,000 × g for 12 min to pellet the platelets. The pellets were
gently resuspended in Hepes Tyrode’s (HT) buffer [10 mM HEPES, 5.56 mM Glucose, 137
mM NaCl, 12 mM NaHCO3, 2.7 mM KCl, 0.36mM NaH2PO4.H2O, 1mM MgCl2.6H2O] pH
6.5 containing PGI2 and 1 mM EGTA. Another centrifugation step was included to
remove any excess [3H]-serotonin and the platelets were resuspended in a sufficient
volume of HT buffer pH 7.4. The concentration of platelets was measured using a Z2
coulter particle counter (Beckman). Calcium (0.7 mM final) was added when
resuspending the platelets for functional assays and 1% fatty acid – free bovine serum
albumin (Sigma) was also added where indicated.
Mouse platelet preparation
Upon exposure of thoracic region, blood was collected by puncturing a ventricle
of the heart with a 25G needle attached to I mL syringe filled with 150 µL 3.8% Sodium
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citrate. The collected blood was diluted 1:1 with 1X PBS and platelets were prepared
using methods similar to what is described above. The samples were centrifuged at 900
rpm for 10 min to separate the RBCs followed by centrifuging the separated PRP at
1,800 rpm for 10 min to pellet down the platelets. Prior to pelleting the platelets, they
were labeled with [3H]-serotonin, when using them for secretion assays. The subsequent
two centrifugation steps were performed with slightly diminished speeds (1,700 rpm).
Platelet secretion assay conditions
Secretion from platelets, stimulated with the indicated agonists, was measured
from 15 to 300 sec at RT. The agonists were thrombin (Chrono-Log, Havertown, PA),
protease-activated-receptor agonists, {[SFLLRN for PAR1] (Bachem, King of Prussia, PA),
[AYPGKF for PAR4] (Invitrogen Corporation, Carlsbad, CA)} and convulxin (Centerchem,
Norwalk, CT). As already described in platelet preparation methods, platelets were
labeled with [3H]-serotonin. An initial titration experiment was performed to determine
the minimal dose required to induce ~90% of maximal [3H]-serotonin secretion in 2 min.
This dose was used for the time-course experiments, which were employed to calculate
exocytosis rates. The doses were: 0.3 U/mL for thrombin, 50 µM for PAR1-agonist, 500
µM for PAR4-agonist, and 0.3 µg/mL for convulxin generally. At the indicated times,
platelets and releasates were separated by centrifugation at 13,000 x g for 2 min. The
platelet pellets were solubilized with buffer (phosphate buffered saline, pH 7.4, 1%
Triton X-100) on ice for 45 min. The releasate and the pellet samples were assayed for
various granule markers as described below.
Detection of the dense granule marker [3H]-serotonin
Radiolabeled serotonin in the releasate and the pellet was measured by liquid
scintillation using Econo-Safe Scintillation cocktail (Research Products International
Corp.) and a TRI-CARB 2100 TR liquid scintillation analyzer (Packard). A percent release
value, at each time point, was calculated following the equation: (cpm in releasate)/cpm
in (releasate + pellet).
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Detection of the α-granule marker Platelet Factor 4 (PF4)
PF4 was quantified by ELISA using reagents obtained from R&D systems (R&D
systems, Minneapolis, MN). The procedure followed for performing the assay and
analyzing the data is summarized here. Human/mouse PF4 capture antibody (2 µg/mL)
in 1X PBS was coated on 96 well microplate (Costar3369 Fisher Scientific) overnight at
RT. Unbound antibody was removed by wash buffer PBS-T (1X PBS pH7.4, 0.05%
Tween20,) and non-specific binding sites were blocked with PBS-T containing 1% BSA
and 5% sucrose for 1 hr. Since PF4 is abundant, the samples were diluted in diluent
buffer (1X TBS pH 7.4, 0.05% Tween20, 0.1% BSA) and 100 µL of it was added to the
wells. The highest concentration of recombinant PF4 employed in the assay as a
standard was 16 ng/mL for human and 2 ng/mL for mouse. This was serially diluted to
construct a standard curve. Sample and capture antibody were incubated for 2 hrs at
RT. The wells were washed with wash buffer and the bound PF4 was detected using a
biotinylated antibody against PF4 (200 ng/mL and 100 ng/mL for human (Leinco
Technologies Inc., St. Louis, MO) and mouse (R & D Systems) respectively). Following
washing, the reaction was developed using HRP-Streptavidin (1:200) and TMB (3, 3’, 5,
5’ Tetra methyl benzidine) substrate (Thermo Scientific). Once the blue color was
achieved, the signal was amplified upon addition of 2M H2SO4 and the OD was read at
450 nm using Elx 808 microplate reader (Biotek Instruments). The data were converted
to a logarithmic scale and were normalized to the generated standard curve. A percent
release of PF4 was calculated following the same equation as above.
Detection of the lysosomal marker β-hexosaminidase
β-Hexosaminidase was detected using a simple colorimetric assay. The substrate,
p-nitrophenyl-N-acetyl-β-D-glucosaminide (PNP-GlucNAc) was resuspended (10 mM) in
the citrate-phosphate buffer (0.2 M Na2HPO4 and 0.1M Citric acid, pH 4.5) and 100 µL
was added into a 96 well microplate together with platelet releasate and pellet sample.
To assure linearity of the assay, a random sample was selected to generate a standard
curve. Equal volumes of the releasate and the pellet samples were added to represent
one whole sample. This was serially diluted to generate a standard curve. The plate was
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sealed and incubated at 37°C for 18 hrs. The reaction was then stopped by the addition
of 1M NaOH to enhance the p-nitrophenyl color and the absorbance of each well was
measured at 405 nm. A percent release of β-hexosaminidase was calculated as above.
Detection of released cargo using micro-ELISA arrays
Several techniques (i.e. mass spectrometry, multiplex bead assay) were
considered for this study; however, it was felt that the micro-ELISA was the best method
to quantify the individual components in the releasate. Custom micro-ELISA arrays were
purchased from RayBiotech (Norcross, GA). The 28 antibodies, from the vendor’s
catalogue of compatible reagents, were distributed between two slides to avoid cross
reactivity. Arrays were blocked for 30 min, and then incubated with 100 µL of standards
or diluted platelet releasates at RT for 1 hr. The arrays were incubated with biotinylated,
detection antibodies and then, with Alexa Fluor 555-conjugated streptavidin, each for 1
hr. The slides were rinsed and scanned with an Axon GenePix (Molecular Devices,
Sunnyvale, CA) microarray scanner using λex = 555 nm and λem = 565 nm (10 mm
resolution). Each antigen was represented by four spots and the average fluorescence
intensity was compared to that from a standard curve of like antigen (generated on the
same array) to determine the concentrations of a cargo antigen in a given platelet
releasate. One array was used to determine the dilution needed to detect all antigens in
the linear range of the assay. In general, the arrays’ sensitivities were pg/mL to ng/mL
(Table 3.2). Array signals were reproducible, differing by < 15% in the nine arrays used
for these studies.
Calculation of a rate constant (Kex)
We cannot directly monitor granule fusion (e.g. by membrane capacitance);
instead, we infer fusion rates from the rates of appearance of cargo outside the platelet.
Analysis was performed using the following reasoning: if a cargo molecule has a fixed
probability per unit time (rate),Kex, of being released when its granule fuses with the
plasma membrane, then the number of cargo molecules remaining at time t after
stimulation is N (t ) = N0 e − Kex t , where N0 is the initial number of molecules. Therefore,
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cargo concentration outside the platelet is complementary to

P (t ) = Pmax (1 − e − K

ex t

), [1] where P

max

N (t ) and is

is the concentration of released cargo at 5 min (the

maximum time of stimulation) normalized to 100%. Raw data were fit to equation [1]
using the curve fit function in IDL (ITT Visual Information Solutions, Boulder, CO) and
confirmed with GraphPad Prism (version 4, GraphPad Software, La Jolla, CA). The curve
fit returns the Mean Squared Error (MSE) defined as MSE = ∑ i =1 (Pi − P (ti )) / ( N − 2) ,
N

2

where Pi is the measured percent release at time ti and P (ti ) is equation [1] evaluated
at ti . The denominator is the number of degrees of freedom where N is the number of
time points from which 2 is subtracted because there are 2 parameters in equation [1].
We used Kex values from only those fits where MSE < 150, taking into account the
unavoidable inherent sampling error. Hence, 90 of 174 kinetic measurements were used
for further analysis.
Note that the MSE is >> 1 only because we have transformed the maximum
concentration to 100. More typical MSE values of <1 are simply obtained upon dividing
by 1002. The criterion MSE < 150 is somewhat arbitrary. We cannot determine if a fit is
acceptable because replicate measurements cannot be done at each time point for all
chemokines individually for all the arrays and we do know the inherent sampling error.
Therefore we used 90 out of 174 kinetic measurements.
Fitting the probability density function
A histogram of all 90 values of Kex, with bin widths of 0.0075 was made. The
probability density function (pdf) was obtained from this histogram by dividing the
number in each bin by the product of the total number of values (90) and the bin width.
The total area under the pdf is 100. To estimate the number of cargo classes, the pdf was
fit to either 2 or 3 Gaussian functions.

 (Kex − µi )2 
f (Kex ) = ∑ Ai exp  −
 , where n = 2 or 3
2σ i2
i =1


n
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[2]

The parameters

(Ai , µi , σ i )

were found

using ProFit

(version 6.0.6,

Quansoft.com, Uetikon am See, Switzerland). We used the F-test to assess whether the
3-Gaussian function fit is statistically better than the 2-Gaussian function fit (Graph Pad
Software Inc. San Diego, CA).
Modeling operator variance
The Kex values vary over a range from 0.00193 s-1 to 0.24 s-1 (Figure 3.13). As our
finest time resolution is 15 sec, timing errors have larger impact for fast release
processes. This results in greater broadening of distribution of the estimated Kex values
even if there were no variation in the intrinsic value of Kex. We exploited this broadening
to estimate the number of cargo classes, the mean Kex value for each class, and the
operator variance

. Factors contributing to the operator variance include timing

errors, pipetting variations, etc. We used the following procedure to study the effect of
operator variance on our analysis. (i) We chose 2 or 3 Kex values to test whether the data
is consistent with 2 or 3 cargo classes. The Kex values were chosen to be the mean values
of the individual Gaussian distributions (Figure 3.12) when the data were fit with 2 or 3
Gaussians. (ii) For each Kex, we computed

, where

time when our measurements were made

and

distributed random number with a mean of 0 and standard deviation
these values of

is the

is a normally
. (iii) Based on

we determined Kex using the same procedure described here. (iv)

Steps (ii) and (iii) were repeated

times. (v) The resulting

of Kex were sorted

by size and plotted as shown in Figure 3.14. The number of samples (
chosen so that the number of different Kex values (2 or 3)

) was

equaled 90, the

number of experimental data points used to construct the pdf shown in Figure 3.12.
Steps (ii) through (v) provide just one particular sample of possible outcomes. We
therefore repeated steps (ii) through (v) 50 times to see the range of possible Kex
estimates. Figure 3.14 shows 90 × 50 Kex values.
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Lipid extraction
Lipids were extracted in acidified organic solvents as described in {Mathews,
2010 #55}. Platelets (50 µL) were added to a mixture of 2 mL CH3OH and 1 mL CHCl3 in 8
mL borosilicate glass tubes and 1 µM C17 S1P (Avanti polar lipids, Alabaster, AL) (50 µL)
was added as an internal standard. The mixture was acidified with 0.45 mL 0.1 M HCl
and the samples were vortexed for 5 min, and then placed at 4°C for 1 h. The extraction
volume was increased by an additional 1 mL CHCl3 and 1.3 mL 0.1M HCl. After vortexing
for 5 min, the samples were centrifuged for 10 min at 4,000 rpm. The lower phase was
then transferred to a 4 mL screw cap glass vial using a glass pasteur pipette carefully
avoiding the protein interface. The samples were evaporated under N2 stream and
resuspended in 100 µL CH3OH.
Detection of S1P by HPLC (ESI) MS/MS
The extracted lipids were analyzed by LC MS/MS. Analysis of S1P was carried out
using a Shimadzu UFLC coupled with a 4000-Qtrap hybrid linear ion trap triple
quadrapole mass spectrometer (AB SCIEX) in multiple reaction monitoring (MRM) mode.
C17 S1P was used as an internal standard. S1P and C17 S1P were separated using Zorbax
Eclipse XDB C8 column (5 µm, 4.6 × 150 mm, Agilent). The mobile phase consisted of
75/25 of CH3OH / H2O with HCOOH (0.5%) and 5 mM HCOONH4 (0.1%) as solvent A and
99/1 of CH3OH / H2O with HCOOH (0.5%) and 5 mM HCOONH4 (0.1%) as solvent B. For
the analysis of S1P the separation was achieved using a gradient of 0% B for 1 min, 0% B
to 100% B in the next one minute, maintained at 100% B for the next 10 min and
equilibrated back to the initial conditions in 3 min. The flow rate was 0.5 mL/min with a
column temperature of 30°C. The sample injection volume was 10 µL. The mass
spectrometer was operated in the positive electron spray ionization mode with optimal
ion source settings determined by synthetic standards of S1P and C17 S1P with a
declustering potential of 61 V, entrance potential of 10 V, collision energy of 23 V,
collision cell exit potential of 16 V, curtain gas of 20 psi, ion spray voltage of 5500 V, ion
source gas1 / gas2 of 40 psi and temperature of 550°C. MRM transitions monitored were
as follows: 366.141/250 for C17 S1P; and 380.124/264.1 for S1P.
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Mouse models
C57BL/6, VAMP-8-/- {Ren, 2007 #56} and Unc13d
generated as described.

Jinx

{Ren, 2010 #57} were

All experiments with animals were under the protocol

884M2005 approved by the University of Kentucky Institutional Animal Care and Use
Committee.
Fluorescence microscopy
Washed platelets (5 × 108 / mL) were incubated with 1 µM mepacrine
dihydrochloride (Sigma Aldrich, St. Louis, MO) or 1 µM lyso tracker red DND – 99
(Invitrogen, Eugene, Oregon) or 1 µM NBD – Sphingosine (Avanti Polar lipids, Alabaster,
AL) for 30 min at 37°C. The platelets were pelleted at 1,600 rpm for 8 min and
resuspended in fresh pH 7.4 HT buffer. Approximately 10 µL of the sample was placed
onto a clean microscope slide and was laid over by a cover glass. The sample was
allowed to settle for 30 min and viewed through 100X objective lens in oil immersion
under Nikon Eclipse 600 (Melville, NY). Digital images were captured using Axiocam
MRm and were processed using Axiovision software.
Thin layer chromatography
Samples, after liquid phase lipid – extraction, were separated by thin layer
chromatography using human banked platelets (Merck KGaA, Darmstadt, Germany) with
a mobile phase of: CHCl3 : CH3OH : H2O in the ratio 60 : 35 : 8. After development and
drying, the separated fluorescently labeled NBD – Sphingosine-containing lipids were
visualized using a Typhoon 9400 scanner (Amersham Biosciences, Piscataway, NJ) at
excitation wavelength 457 nm and emission wavelength 532 nm. We thank Dr. Binks
Wattenberg at University of Louisville for providing NBD – Sphingosine-1-phosphate
standard for this analysis.
Sub – cellular fractionation
The procedure was modified from Broekman 1992 (Broekman, 1992). A unit of
fresh PRP from KBC was centrifuged at 800 rpm for 15 min. Platelets were pelleted at
1,800 rpm for 15 min at RT and pellet was washed twice with 50 mL Tris - citrate buffer
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(63 mM Tris, 95 mM NaCl, 5 mM KCl, 12 mM citric acid, pH 6.5/ HCl). The platelet pellet
was finally resuspended in 12 mL Tris - citrate buffer and was then poured into the
chamber of cell disruption bomb (Parr 4639, Parr Instrument Co., Moline, IL). The Parr
bomb was pressurized with N2 at 1,200 psi on ice for 15 min and the pressure was
rapidly released to disrupt the cells. This cycle was repeated thrice and the platelet
homogenates were cleared by centrifugation at 2,500 rpm for 10 min to remove cell
debris and partially disrupted cells, prior to loading onto sucrose gradients. Roughly
linear sucrose gradients were generated by layering 1.5 mL sucrose solutions (containing
5mM EDTA) of decreasing concentrations (from 60% to 30%, total 10.5 mL) into a 14 mL
ultracentrifuge tube and the tubes were incubated overnight at 4°C. Homogenate (1.5
mL) was layered onto the top of the gradient and they were subjected to centrifugation
at 40,000 rpm at 4°C using SW - 40 swinging - bucket rotor (Beckman, Fullerton, CA).
After 90 min the tubes were recovered and snap - frozen in an ethanol/dry - ice bath and
then placed at -80°C overnight. The frozen tubes were cut into 10 equal sizes (~1.2mL)
using a clean steel saw. The fractions were then recovered and 200 µL of each fraction
was diluted to 1mL with H2O. After adding 100 µL of 2% Sodium deoxycholate and 200
µL of 72% tri chloro acetic acid (TCA), the samples were incubated on ice for 30 min
followed by centrifugation at 13,000 × g for 10 min to recover the precipitated proteins.
The pellets were washed with 1 mL of cold acetone, dried, and resuspended the pellet in
100 µL of 2X SDS sample buffer for analysis by SDS-PAGE and western blotting.
Western blotting
Samples recovered by TCA precipitation as described above were separated (15
µL) on 12.5% SDS-PAGE at 200 V for 45 min. The separated proteins were then
transferred onto Immobilon-P polyvinylidene fluoride (PVDF) membrane (Millipore
Corp., Bedford, MA) for 1 hr at 100 V in 1X transfer buffer (25 mM Tris, 192 mM Glycine,
20% Methanol pH 8.3). The PVDF membrane, with the transferred proteins, was initially
blocked for 1 hr at RT with 5 % non-fat milk in TBS-T (25 mM Tris, 150 mM NaCl, 0.1%
Tween-20 pH 7.4). This was followed by incubation with the primary antibody (diluted in
blocking buffer) against indicated proteins (αIIbβ3, Rab-GDI, VAMP-8, malate
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dehydrogenase, PF4) overnight at 4°C. Anti-αIIbβ3 rabbit polyclonal antibody was a
generous gift from Dr. Bill Dean at University of Louisville. Anti-RabGDI polyclonal
antibody was generated in our laboratory by Dr. Tara Rutledge using recombinant
RabGDIα as antigen. Polyclonal rabbit-anti-human VAMP-8 was generated in our
laboratory using recombinant cytoplasmic domain of human VAMP-8 (1-73 aa).
Antibody against Malate DHase was a generous gift from Dr. Louis Hersh at University of
Kentucky. After washing with TBS-T, the membrane was incubated with appropriate
dilution of alkaline-phosphatase conjugated secondary antibody (Sigma) for 1 hr at RT.
Following washing, the membrane was incubated for 5 min at RT with Vista-ECF
substrate (Amersham Biosciences, Piscataway, NJ). The immunodecorated proteins were
visualized using Typhoon 9400 scanner (Amersham Biosciences, Piscataway, NJ) at
excitation wavelength 457 nm and emission wavelength 555 nm.
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Chapter Three
Heterogeneity in Platelet Secretion
Introduction
Platelets are first responders to vascular damage. The damaged vasculature
attracts and activates platelets to release cargo from granular stores: dense (δ), alpha
(α), and lysosomal. Dense granules contain small molecules (i.e. ADP, and serotonin) (Ge
et al., 2009; Holmsen and Weiss, 1979; McNicol and Israels, 1999). α-Granules contain
polypeptides (Maynard et al., 2010) and lysosomes contain hydrolytic enzymes (i.e. βhexosaminidase and cathepsins) (Holmsen and Weiss, 1979). Release of dense granule
cargo is important to hemostasis, given the bleeding diatheses associated with genetic
defects in dense granule biogenesis (i.e. Hermansky-Pudlak Syndrome, HPS) (GunayAygun et al., 2004). Released ADP enhances the responsiveness to other agonists
generated at the site of vascular damage (Graham et al., 2009). Release of α-granule
cargo has a more heterogeneous impact. Patients that lack α-granules (i.e. Gray Platelet
Syndrome, GPS) generally have more diverse bleeding phenotypes, ranging from severe
to mild (Gunay-Aygun et al., 2010; Nurden and Nurden, 2007). The role that lysosome
release plays is unclear; the released hydrolytic enzymes could be important for
thrombus remodeling. While it is clear that platelet secretion is important, it is not clear
how the platelet release reaction modulates the microenvironment at vascular injury
sites.
Present estimates suggest that activated platelets secrete hundreds of different
molecules (Maynard et al., 2007; Senzel et al., 2009). While dense granules
predominantly contain small molecules, α-granules contain a myriad cargo that comprise
the bulk of the platelet “secretome”. α-Granules contain hemostatic factors (e.g. Factor
V, fibrinogen), angiogenic factors (e.g. angiogenin, VEGF), anti-angiogenic factors (e.g.
angiostatin, PF4), growth factors (e.g. PDGF, SDF1α), proteases (e.g. MMP2, MMP9),
necrosis factors (e.g. TNFα, TNFβ) and other cytokines(Coppinger et al., 2004). Some are
produced by megakaryocytes and are packaged into granules during their biosynthesis
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(Heijnen et al., 1998). Patients with GPS presumably have a defect in this process. Other
α-granule cargo (e.g. fibrinogen and Factor V) are not made by megakaryocytes but are
thought to be endocytosed by circulating platelets (Louache et al., 1991). They are then
transported to α-granules (Harrison et al., 1989; Heijnen et al., 1998).
The catalog of cargo suggests that platelet secretion is pivotal to establishing the
microenvironment at an injury site. However, very little is understood about how
platelet secretion occurs. Studies suggest that certain angiogenesis regulators are
packaged into distinct populations of α-granules. Immuno-fluorescence and immunoelectron microscopy show distinct localizations for pro- and anti-angiogenic factors
(Italiano et al., 2008). Consistently, other studies have shown that stimulating platelets
with different agonists (i.e. PAR1- and PAR4-agonists) causes differential release of
certain cargo (Chatterjee et al., 2011; Folkman, 2007; Italiano et al., 2008; Ma et al.,
2005). This led to the proposal that platelet secretion is contextually thematic: capable
of releasing specific sets of cargo (e.g. pro- or anti-angiogenic factors) in response to
specific agonists (Folkman, 2007; Italiano et al., 2008). More recent studies have
suggested that cargo is spatially segregated into sub-regions of the same membrane
bound granules and that there is little co-localization of factors with like functions
(Kamykowski et al., 2011; Sehgal and Storrie, 2007). Though intriguing, it is difficult to
ascertain how platelets release their myriad cargo in response to the agonists generated
at the site of vascular damage. Addressing this question is significant since, if there is
heterogeneity in cargo packing and/or secretion, regulating the release of specific αgranule sub-populations may allow specific manipulation of the microenvironment at an
injury site without disturbing hemostasis. Our study offers the first systematic
examination of the platelet secretion process and its kinetics, and potential
heterogeneity.
To define the extent of platelet secretion heterogeneity, we measured the
release of serotonin, β-hexosaminidase, and 28 different α-granule cargo proteins. These
proteins have a diverse range of biochemical properties, functions, and origins. Four
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different agonists (PAR1- and 4-agonists, thrombin, and convulxin) were used to
stimulate release and secretion time courses were measured with micro-ELISA arrays.
The time course data was fit to a one phase exponential equation to calculate release
rate constants for each cargo molecule detected. These rate constants were analyzed to
identify patterns in the release kinetics. In general, the number of α-granule cargo
proteins detected in platelet releasates correlated with agonist potency (thrombin >
convulxin/PAR1 > PAR4). Though some cargo was more rapidly released than others, no
coherent, functional pattern was observed. Detailed analysis of the release rate
constants indicated that platelet release heterogeneity is kinetically-based and can be
defined as three classes of events (fast, intermediate and slow).
Agonists used for stimulating platelets
Thrombin is a potent agonist that has been employed mostly throughout the
study. As described in Chapter One, thrombin acts via PAR1 and PAR4 receptors on
human platelets. The reaction is inhibited at the end of stimulation of platelets by using
hirudin. Hirudin is an anti-coagulant derived from leeches (Baskova et al., 1983; Chang,
1983). It directly binds to the serine protease, thrombin, and inhibits its cleavage of
PARs. This ability to stop the reaction with an inhibitor is not possible when using other
agonists chosen for this study. Upon centrifugation the releasate and the pellet fractions
were rapidly separated in an attempt to stop the release reactions induced by convulxin,
PAR1- and 4-agonists. The release of contents during this work up period is unavoidable
and slightly lessens the resolution of the time course experiments.
Characteristics of granule secretion from platelets
Granule release upon thrombin stimulation
Platelet granule populations are distinguished into three classes based on their
morphology, abundance, and contents. They include dense granules, α-granules and
lysosomes. Platelet secretion was analyzed in a series of time-course experiments,
initially using different concentrations of thrombin as agonist. Release of [3H]-serotonin,
as a metric of dense granule release; PF4, as a metric of α-granule release; and β41

hexosaminidase, as a metric of lysosome release was measured as previously reported
{Chen, 2000 #107;Schraw, 2003 #95}. The thrombin doses used were 0.025 U/mL (a),
0.05 U/mL (b), 0.1 U/mL (c) and 0.4 U/mL (d). There was no detectable dense granule
secretion upon treatment with 0.025 U/mL thrombin. A 30%, 40%, and 60% dense
granule release was seen at 0.05 U/mL, 0.1 U/mL and 0.4 U/mL thrombin stimulation
respectively. α-Granule exhibited 20%, 35%, 40% and 50% release, respectively. The
same increasing pattern could be seen in lysosomal release. The idea that the extent or
the rapidity of release is dependent upon the agonist dose can be visualized through
Figure 3.1.
The data from the experiment described above was plotted to represent
different granule (dense granule, α-granule and lysosome respectively) release patterns
(Figure 3.2). Dense granule release was undetectable when platelets were stimulated
with 0.025 U/mL thrombin while markers from the other two granules could be detected
in the releasate. At high thrombin concentrations (0.4 U/mL of thrombin) dense granule
release was maximal (~60%); α-granule release was 50%; and, lysosomal release was
30%. This release feature has been examined in 28 different proteins that are known to
get secreted from platelets. The purpose of doing such analysis was to test if the concept
of agonist potency determining the extent of secretion holds good for a broader group
of secreted proteins.
Secretion assay conditions
An initial titration experiment was done for every trial performed to estimate the
agonist concentration to be used. The choice was determined by the ability of the
agonist to release between 80-90% of [3H]-serotonin from platelets upon stimulation
with the chosen agonist for 2 min (Figure 3.3). The same strategy was employed for all
the agonists used in the study (thrombin (a), convulxin (b), PAR1 (c)) except for PAR4
where doing a titration every time was limited by the cost of the peptide. A maximum
concentration of PAR4 (500 µM) was used for the study. By choosing the maximal
concentration of each agonist for our analysis we assured that stimulation was optimal
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and thus the release kinetics reflected platelet exocytosis process and not differential
activation. Since different extents of platelet activation could account for secretion
heterogeneity, we chose this strategy to lessen that variable and focus the analysis on
release and not activation. Apyrase was included during platelet isolation to lessen the
effects of released ADP. Platelets were not stirred. [3H]-serotonin, PF4 and βhexosaminidase release characteristics were used to standardize assay conditions.
Agonist dependency of cargo release
The release of serotonin, PF4, and β-hexosaminidase is considered as an
evidence that secretion from dense granules, α-granules, and lysosomes has occurred,
respectively. In agreement with previous studies (Balduini et al., 2002; Blair and
Flaumenhaft, 2009; Ren et al., 2008), the relative release rates at the earlier time points
were consistent - serotonin > PF4 > β-hexosaminidase, regardless of the agonist used.
Agonist dose dependency on the release of granule cargo represented in Figures 3.1 and
3.2 holds good not only for thrombin but also, convulxin, PAR1- and PAR4-agonists.
Release of serotonin (Figure 3.4, ■), was most rapid and was generally the most
extensive (highest percent release). Release of PF4 (Figure 3.4, ▲) was more extensive
than that of β-hexosaminidase and did approach that of serotonin, especially when PARagonists were used. Release of the lysosomal cargo, β-hexosaminidase (Figure 3.4,),
was the least extensive. Interestingly, the extent of β-hexosaminidase release was most
sensitive to agonist. Release induced by thrombin and convulxin was two-fold higher
than that induced by either of the PAR-agonists. Serotonin and PF4 release were
similarly affected by the agonist used, but not to the same degree.
Agonist potency affected the extent of cargo release. Strong agonists such as
thrombin (Figure 3.4A) and convulxin (Figure 3.4B) induced rapid release that was
extensive, reaching approximately 70% of total for serotonin, 50% for PF4, and 30% for
β-hexosaminidase. With PAR1-agonist (Figure 3.4C), release kinetics were similar but
the extents of release were less. PAR4-agonist stimulated release of the three markers
was uniformly slower and less extensive (Figure 3.4D). Perhaps not surprisingly, these
43

results imply that the degree of platelet activation is directly reflected in the speed
and/or magnitude of cargo release. Weaker agonists such as PAR4-agonist stimulated
only partial release while stronger agonists such as thrombin stimulated rapid and
nearly complete release of intra-platelet stores of cargo. This is most obvious in the
release of lysosomal cargo.
Detection of the selected α-granule cargo
To probe the releasates for specific cargo proteins, custom micro-ELISA arrays
were produced. This micro-ELISA configuration allows for simultaneous quantification of
multiple proteins from the same releasate sample. The antigens to be detected were
chosen based on their proposed functions (growth factor, angiogenic factor, cytokine,
etc., Table 3.1) and on the availability of suitable antibodies. The sensitivity of detection
was in the pg/mL to ng/mL range. The entities probed for are listed in Table 3.2 are
detected through ELISA as described in Chapter Two.
Release of α-granule cargo
The percent release of multiple protein cargo released upon platelet stimulation
is represented in Figure 3.5. The lowest time point of secretion from platelets that could
be analyzed was 15 sec. It has to be kept in mind that the details of cargo release within
these 15 sec cannot be addressed by this study due to manual limitation. The data
shown in Figure 3.5 is representative of several individual trials. In this pool of release
data, it could be seen that the moieties that are released from platelets within a span of
5 min are released at different rates. The analysis done subsequently involved scrutiny of
the rate constants of individual cargo released. Manual observation and mathematical
tools served this purpose as will be seen from here on.
Differential release of α-granule cargo
We next sought to qualitatively determine if there were agonist-dependent
differences in α-granule cargo release in response to different agonists. Micro-ELISA
arrays and our standard assays were used to monitor the release of 30 different cargo
molecules (28 are thought to come from α-granules). Platelets were stimulated with
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optimized doses of agonists for 5 min and the releasates were probed (Figure 3.6).
Twenty nine cargo molecules were detected at least once in the releasates from
thrombin-stimulated platelets (3 trials) while only 17 were detected at least once when
PAR4-agonist was used (2 trials). Twenty seven cargo molecules were detected in
releasates from convulxin-stimulated platelets (2 trials) and PAR1-agonist induced the
release of 23 different cargo molecules (2 trials). Seven were released upon thrombin
stimulation that were not released by PAR1-agonist stimulation. Three were released in
response to thrombin but not in response to convulxin. No cargo molecule was released
only in response to thrombin or only in response to convulxin. When platelets from a
single donor were stimulated with the 4 agonists, thrombin (26 released) and PAR1agonist (23 released) induced the release of more proteins than did convulxin (16
released) or PAR4-agonist (17 released). The discordant response to convulxin by
platelets from this single donor is not clearly understood.
When the compositions of the releasates from PAR1- and PAR4-agonist
stimulated platelets were compared, there were clear differences. Eight cargo molecules
were specifically released only in response to PAR1-agonist while only 2 specifically
appeared in the releasates with PAR4-agonist (Figure 3.6). There were no obvious
functional patterns to these differences. As an example, release of the 3 angiogenic
regulators (angiostatin, oncostatin M, and angiogenin), were induced by both agonists.
These data show that PAR4-agonist, on average, does not induce release of as many
different molecules as does thrombin, convulxin or PAR1-agonist.
Calculation of release rate constants
The data above offer a qualitative analysis of platelet secretion at a specific time point,
post-stimulation. To more fully characterize platelet secretion and to identify potential
release patterns, we sought a metric that was less affected by the extent of cargo
release and more indicative of the secretion process. Thus, we analyzed the kinetics of
platelet exocytosis by measuring the rate constants describing the release of each cargo
molecule. Agonist-induced, release time-course measurements were made using micro45

ELISA arrays and the data were fit to the function Pt = Pmax (1-e

–Kext

) (1). The logic

supporting the use of this function is described in Chapter Two. The rates of release of
each granule type when platelets were stimulated for 2 min with four different thrombin
doses (0.025 - 0.4 U/mL) were calculated (Figure 3.7). Thrombin dose Vs rate (Kex) graph
was plotted. Serotonin release rate was higher than that of PF4, which is followed by βhexosaminidase. This implies dense granule release > α-granule release > lysosomal
release.
Extending this calculation of release rate constant to 28 different cargo
molecules involved filtering of available release data. For most α-granule and lysosome
cargo, sufficient data was available for good fits to the function with MSE < 150. Out of a
pool of 174 total kinetic measurements, the data utilized for further analysis passed
equation 1 with MSE < 150. This step was added to filter the available data. Only 90 out
of 174 measurements met the criterion of MSE < 150. Representative release fits are
shown in the Figure 3.8. By extending the criterion to MSE < 250, 106 of 174 granule
release measurements could be used. Representatives of such analysis could be seen in
Figure 3.8, panels E and F. Note that the MSE is >> 1 only because we have transformed
the maximum concentration to 100. More typical MSE values of < 1 are simply obtained
by dividing with 1002. The criterion MSE < 150 is somewhat arbitrary. An inherent
sampling error is inevitable as replicate measurements cannot be done at each time
point for all cargo molecules on each array. Therefore we cannot statistically confirm
whether a fit is acceptable.
Analysis of cargo release kinetics
The calculated Kex values were used as descriptors to compare the release
kinetics of different cargo molecules, regardless of the extent to which the cargo was
released. Four types of analyses were applied to these values. The first was a simple rank
ordering (largest Kex to smallest; fastest to slowest) followed by an, albeit artificial, tertile
sorting of the data (Table 3.3). We sought to determine if the release rates for a given
molecule in response to a specific agonist were in the fastest or slowest third and if
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there were patterns in the distribution. When measurements allowed, serotonin release
was always in the fastest tertile, regardless of the agonist used. PF4 release was in the
fastest tertile in response to 3 (thrombin, convulxin, and PAR1-agonist) of the 4 agonists
tested. β-Hexosaminidase release was in the fastest tertile twice as were ANG, CD62P,
and MIP1α release. SDF1α, TGFβ, EGF, MIP1δ, GROα, IL-1α, IL-1β, TNFβ and TIMP4 were
at least found twice in the slowest tertile. PDGF release was in the middle tertile in
response to 3 of the 4 agonists (convulxin, PAR1 and PAR4-agonists). Angiostatin and
TARC release showed no consistent pattern and ranked in each of 3 tertiles in response
to the 4 agonists used. There were no obvious patterns to how molecules were released.
Illustrative of this, release of the angiogenic regulators, angiogenin, angiostatin, and
oncostatin M were distributed in all 3 tertiles.
We next determined if the release rates correlated to any biochemical property
of the cargo molecules. We plotted Kex versus molecular weight (Figure 3.9), relative
abundance (Figure 3.10), and isoelectric point (as a metric of relative charge; Figure
3.11). Linear regression analysis of these data showed no R2 values that reached
significance. This indicated that the release rates, as measured by Kex values, did not
directly correlate to any of these three biochemical properties. Of note, Kex values did
not show linear relationship with relative abundance, suggesting that platelet secretion
is not simply a function of cargo concentration or abundance.
Probability density function analysis
A probability density function (pdf) is a scaled histogram function where the area
under the curve is made to equal 100. This analysis included 90 Kex values (MSE <150)
shown by the bars in Figure 3.12. The heavy black curve is the 3-Gaussian function fit
and the colored dashed curves are the individual Gaussian functions (Figure 3.12 top
panel). The means of the 3 Gaussians are 0.010, 0.067, and 0.148 s-1. Similar distribution
was seen when the larger dataset of Kex values (MSE <250) was used (Figure 3.12,
bottom panel). These results suggest that the release rates cluster into 3 classes with
distinct means. Serotonin, when accurate measurements were made, was always in the
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fastest class (Figure 3.13). TNFβ was in the slowest class in response to three of the four
agonists. Release of TNFα, IL-1β, or EGF (when detectible) was always in the slowest
class. TNFβ, angiostatin, PF4, and β-hexosaminidase release showed no consistent
pattern and ranked in each of the three classes in response to the four agonists used.
TNFβ release was in the fastest class once and the slowest class three times. As with the
ranked-tertile analysis, no obvious functional patterns were detected. Release of the
angiogenic regulators, angiostatin, VEGF, and oncostatin M were either in the middle or
in slowest class while release of angiogenin occurred in all three classes. From this
analysis, we conclude that there are three kinetically-distinct classes of cargo release.
Operator variance analysis
To confirm our conclusions, we examined how operator variance would affect the
values of Kex using the procedure described in Chapter Two. The questions posed were:
(1) how many cargo classes are there and (2) what are the mean Kex values for each
class. Figure 3.14 shows the distribution of the calculated Kex values (open symbols)
assuming 3 cargo classes with Kex values equaling the mean values obtained from the 3Gaussian distributions in Figure 3.12. The Kex values used were 0.010, 0.067 and 0.148 s1

. The solid symbols are from the 90 Kex values obtained from our experiments. The Index

is simply the ordinal number of the Kex value. There is overlap of the experimental and
simulated Kex values in the low and high index ranges but not in the middle range. To
obtain a better overlap, we adjusted the middle rate constant to 0.033 s-1. Panel B shows
that this adjustment produces a much better overlap. Assuming 2 cargo classes with Kex
= 0.010 s-1 and 0.148 s-1 results in the distribution shown in panel C. The “breaks” in the
simulated and actual Kex distributions occur at different places. Changes in Kex did not
improve the overlap. This result supports the F-test result (noted in Chapter Two)
indicating that the 3-Gaussian fit is statistically superior to the 2-Gaussian fit.
The distributions in the panels A, B, and C were generated using σ op = 0.2. To
estimate the operator variance we changed σ op between 0 and 0.3. Panel D shows the
result when σ op = 0.1 and Kex = 0.010, 0.033 and 0.148 s-1. The overlap is poorer
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compared to panel B and, notably, the breaks in the distributions occur at different
indices. σ op = 0 produces 3 discontinuous horizontal distributions at Kex = 0.010, 0.033
and 0.148 s-1. When σ op = 0.3, the data was so poor that we could not fit the data to
equation (1). Therefore, the operator variance is between 0.1 and 0.3, and most likely
0.2.
Cargo molecules do not consistently associate with one class
To determine if a cargo molecule was consistently released via one kinetic class,
we examined the Kex values of 9 cargo molecules that were detected in 4 or more
experiments. The Kex values are given in Table 3.4. The last row is the ratio r of the
largest to smallest Kex value for that cargo molecule. If a cargo molecule is always present
in one kinetic class then r would be ~1. However, r ranges from about 3 to 80. TNFα has
the smallest r value of 3.3 with the smallest Kex equaling 0.0210 and the largest 0.0691 s1

. The larger Kex is likely to be part of the fast kinetic class whose mean value is 0.148 s-1

while the smaller 3 Kex values are likely to be part of the medium class whose mean is
0.033 s-1. Angiogenin, PDGF, and serotonin appear in the fast and medium classes while
angiostatin, SDF1α, TNFβ, and PF4 appear in all 3 classes.
Agonists do not activate only one cargo class
If an agonist were to activate only a single cargo class, then the Kex values
measured with that agonist would cluster about a single value. To test this hypothesis,
we generated pdfs of Kex values obtained in experiments where the platelets were
stimulated with thrombin, PAR1-agonist, or convulxin. We did not use the PAR4-agonist
data because the number of acceptable Kex values (n=11) was too small for a sensible
pdf. We had 43 Kex values for thrombin, 19 for PAR1-agonist and 17 for convulxin. Figure
3.15 shows the pdfs for the 3 agonists. The 3 Gaussian functions used to generate the
best-fit distribution in Figure 3.12 are superimposed on the pdfs. The individual pdfs
follow approximately the 3 Gaussian functions suggesting that the 3 agonists activate all
3 cargo classes.
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Discussion
The presented work is the first systematic analysis of human platelet secretion in
which the release kinetics of multiple cargo molecules is examined. We simultaneously
measured the time-dependent release of 30 distinct molecules from platelets stimulated
separately with 4 different agonists. Agonist concentrations were chosen to maximize
release and to minimize the ambiguities of partial platelet activation. Our qualitative
analysis (Figure 3.6 and Table 3.3) shows that the extent and rate of release are related
to agonist potency: thrombin induced the most rapid release of the highest number of
cargo molecules and the PAR4-agonist induced the slowest, least extensive release.
There were no overt functional patterns in what was released when comparing the
responses to the four agonists tested. Release speed (as represented by Kex) did correlate
with agonist potency (and agonist dose, data not shown) but not with molecular weight,
charge, or abundance of the cargo (Figures 3.9-3.11). Our quantitative analyses of the
distribution of Kex values indicated that platelet secretion could be minimally described
as the summation of 3, kinetically-distinct classes of release events (Figure 3.12).
Distribution of cargo into these kinetic classes did not correlate with overt functional
patterns. A recent report (Kamykowski et al., 2011), suggests that α-granule cargo are
stochastically packaged into subdomains within single granules, not segregated into
specific granule subclasses. If packaging is random, then one might expect that platelet
cargo release is a stochastic process controlled by other factors such as granule-plasma
membrane fusion rates. Our data are consistent with that expectation.
Platelets have the potential to control the vascular microenvironment through
the myriad molecules they secrete upon activation (Brass, 2010). The work of Italiano et
al (Italiano et al., 2008) and others (Chatterjee et al., 2011; Ma et al., 2005) suggested
that pro- and anti-angiogenic factors could be differentially released in response to
specific agonists. In general, these studies measured secretion at single time points (or
agonist concentrations) making them difficult to compare with the kinetic
measurements presented here. It is possible that the observed release heterogeneity
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could be a function of partial platelet activation. Based on a detailed examination of our
secretion time-courses and agonist titrations, one could devise specific conditions that
could result in what appears to be thematically-differential release of platelet cargo.
These conditions represent specific stages in the activation process and may not reflect
the continuum of events occurring in a growing thrombus. Our choice of reaction
conditions limited this variable and focused our analysis on the secretion process. At the
site of vascular damage, the extent of platelet activation may be stratified and thus
granule release may vary both spatially and temporally. Future studies of in situ platelet
secretion are needed to fully understand platelet exocytosis; however, our data suggest
that focus should be placed on the kinetics of the process.
Our analyses suggests that platelet release is best described as the summation of
at least three classes of release processes differing in rate even though the distribution
of cargo into each class is random. To conceptualize this we use a postal system analogy.
The mailmen are the platelets delivering the granule cargo (the mail). There are three
mail classes: Express, 1st Class and Bulk; each arriving at different rates. Serotonin, in
dense granules, was the only true Express cargo; other α-granule cargo was distributed
into all three classes. This implies that, aside from serotonin, the mail sorters are blinded
to content and thus inclusion into each of the three mail classes is random. Random
sorting of α-granule cargo is consistent with the lack of thematic co-localization of cargo
reported by Storrie and colleagues (Kamykowski et al., 2011; Sehgal and Storrie, 2007).
The distinction between dense (i.e. serotonin) and α-granule cargo is also consistent
with the fact that two distinct sorting machinery are required to make the two classes of
granules (Bonifacino, 2004). How kinetic heterogeneity in α-granule cargo release is
generated remains to be determined.
Simplistically, regulated exocytosis is the stimulation-dependent fusion of
spherical, cargo-containing granules with the plasma membrane. A variation on this,
compound fusion, occurs when granules fuse with each other prior or subsequent to
fusion with the plasma membrane. The granules can be homogeneous (e.g. synaptic
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vesicles in neurons) or heterogeneous (e.g. azurophil, peroxidase negative, etc. granules
in neutrophils). In homogeneous systems, release occurs with two general kinetic
components: burst and sustained. The rapid, burst phase represents vesicles that are
docked with their secretory machinery primed for fusion (as perhaps seen for dense
granules). The sustained phase represents release from vesicles that must be recruited
to fusion sites. In heterogeneous systems, the different granule populations are thought
to have distinct properties. At a first approximation, platelets are examples of the latter
class. Dense granule release is more rapid than α-granule or lysosome release; a trend
that held true for all agonists tested here (Figure 3.4 and 3.13). Since release from all
three granules requires the same SNAREs (VAMP-8 (Ren et al., 2007), SNAP-23 {Chen,
2000 #97;Chen, 2000 #107;Flaumenhaft, 1999 #101;Lemons, 2000 #106}, and syntaxin11 (Ye et al., 2012)) and at least two of the same SNARE regulators (Munc18b (Al Hawas
et al., 2012) and Munc13-4 (Ren et al., 2010)) it is unclear how secretory machinery
usage explains the observed differences. However, loss of VAMP-8 has a greater effect
on PF4 release (Ren et al., 2007). Deletion of Munc13-4 has a greater effect on serotonin
release (Ren et al., 2010). Loss of syntaxin-11 (Ye et al., 2012) or Munc18b (Al Hawas et
al., 2012) affected serotonin and PF4 release more than β-hexosaminidase release. Thus
differential use or regulation of the same secretory machinery could account for
differences between the three granule populations. Alternatively, the underlying kinetic
patterns might reflect the types of membrane fusion. Platelet granules (specifically αgranules) do undergo compound fusion during the exocytosis process (Valentijn et al.,
2010). The rates of these two types of membrane fusion (primary and compound) could
partially account for the differential release kinetics, reported here. Another possibility
may relate to the distribution of cargo proteins. Cargo is heterogeneously distributed
inside a granule (van Nispen tot Pannerden et al., 2010) and differential solubilization of
these “cargo clusters”, once granule and plasma membranes fuse, could underlie release
heterogeneity. These explanations (as are our mathematical analyses) are based on the
concept that platelet granules are spherical, like synaptic vesicles. Recent ultra structural
analysis (van Nispen tot Pannerden et al., 2010) indicates that α-granules may in fact be
52

tubular and thus their fusion could be polarized. Fusion at one end of a tube might cause
differential release rates as the tube empties, depending on where in the tube the cargo
resides. At this stage it is impossible to be more than speculative about the
mechanism(s) until more “real-time” in situ measurements of platelet cargo release are
obtained. Though these data provide insight into how platelets release their cargo, still a
lot has to be learned.

Copyright © Deepa Jonnalagadda 2013
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Table 3.1. Cargo molecules probed in the secretion assays

Listed are the cargo molecules probed on the micro-ELISA arrays. Their abbreviated
names (Symbol) are indicated in the middle column. The cargo molecules are grouped
according to their proposed functions (left-most column).
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Table 3.2. Detection ranges of the probed cargo molecules

The maximum and the minimum concentrations (pg/mL; except for ANG, which is listed
as ng/mL) of the released cargo detectible by the micro-ELISA arrays are indicated. These
values are based on the standard curves generated for each cargo antigen.
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Table 3.3. Tertile ranking of Kex values

Human platelets (1.2×109 /mL) were prepared as described and stimulated with
thrombin (0.3 U/mL; n = 3), convulxin (0.3 µg/mL; n = 2), PAR1-agonist (50 µM; n = 2), or
PAR4-agonist (500 µM; n = 2) for 5 min. Releasates were probed using micro-ELISA arrays
to obtain the rate constant Kex for each cargo molecule. The average Kex value was
calculated for each cargo released upon stimulation of platelets with each agonist. The
cargo was grouped into tertiles with no bias, based on Kex values in descending order.
The cargo in blue fall into fastest tertile, in green are the intermediate tertile, and the
red category belong to the slowest tertile.
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Table 3.4. Representation of cargo packaging by kinetics of release

Cargo

Kex
Values

r

Angiogenin

Angiostatin

PDGF

SDF1α

TARC

TNFα

TNFβ

Serotonin

PF4

0.0247
0.0266
0.0349
0.0466
0.0674
0.1321
0.1326

0.0024
0.0125
0.0288
0.0365
0.0635

0.0214
0.0306
0.0480
0.0728
0.0747
0.1398

0.0027
0.0292
0.0340
0.0370
0.1644

0.010
3
0.020
5
0.026
2
0.109
1

0.0210
0.0288
0.0263
0.0691

0.0019
0.0176
0.0207
0.0239
0.1535

0.0264
0.0672
0.0934
0.1657
0.2176

0.0083
0.0086
0.0390
0.0645
0.0732
0.1299
0.1529

5.37

26.86

6.52

62.00

10.57

3.29

79.73

8.23

18.32

Listed are the Kex values of 9 different cargo molecules found in 4 or more releasate
trials. The last row represents the ratio, r, of the largest to the smallest Kex of the
corresponding cargo.
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Figure 3.1. Thrombin dose dependence of granule release
Human platelets (3×108 /mL) were prepared as described and the samples were
stimulated with 0.025 U/mL, 0.05 U/mL , 0.1 U/mL and 0.4 U/mL thrombin as
represented in panels a, b, c and d respectively. The reaction was carried over 2 min with
intermittent time points. Thrombin stimulation was stopped with 0.05 U/mL, 0.1 U/mL,
0.2 U/mL and 0.8 U/mL hirudin respectively, followed by centrifugation. Release from
the three classes of granules was measured using the marker cargo molecules: [3H]serotonin for dense granules (black), PF4 for α-granules (red) and β-hexosaminidase for
lysosomes (blue). Percent release was calculated using the equation [(Releasate)/ (Pellet
+ Releasate)] x 100. Measurements at each time point for each thrombin dose were
done in triplicate, and the averages with standard deviations are indicated.
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a

b

c

Figure 3.2. Granule exocytosis from platelets
Human platelets (3×108 /mL) were prepared as described and the samples were
stimulated with 0.025 U/mL (blue,

), 0.05 U/mL (green, ), 0.1 U/mL (red, ) and 0.4

U/mL (black, ♦) thrombin as represented in panels a, b and c. The reaction was carried

over 2 min with intermittent time points. Thrombin stimulation was stopped with 0.05
U/mL, 0.1 U/mL, 0.2 U/mL and 0.8 U/mL hirudin respectively, followed by centrifugation.
Release from the three classes of granules was measured using the marker cargo
molecules: [3H]-serotonin for dense granules (a), PF4 for α-granules (b) and βhexosaminidase for lysosomes (c). Percent release was calculated using the equation
[(Releasate)/ (Pellet + Releasate)] x 100. Each time point, at each thrombin dose was
measured in triplicate and the averages with standard deviations are indicated.
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a

b

c

Figure 3.3. Agonist titration
Fresh human platelets were isolated (1.2×109 /mL) after incubating them with [3H]serotonin for 45 min. They were stimulated with increasing doses of thrombin (a),
convulxin (b) or PAR1 (c). The reaction was stopped with hirudin at the end of 2 min in
(a). For convulxin and PAR1 treated samples the reactions were stopped by
centrifugation. Percent release was calculated using the equation [(Releasate)/ (Pellet +
Releasate)] x 100 (see Chapter Two).
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Figure 3.4. Time course of release from activated platelets
Human platelets (1.2×109 /mL) were prepared as described and were stimulated with
thrombin (0.3 U/mL, A), convulxin (0.3 µg/mL, B), PAR1-agonist (50 µM, C), or PAR4agonist (500 µM, D) for the indicated times. Thrombin stimulation was stopped with
hirudin (0.6 U/mL) followed by centrifugation; the rest of the reactions were stopped by
centrifugation and the releasates were recovered. Release from the three classes of
granules was measured using the marker cargo molecules: [3H]-serotonin for dense
granules (), PF4 for α-granules () and β-hexosaminidase for lysosomes (). Percent
release was calculated using the equation [(Releasate)/ (Pellet + Releasate)] x 100. Each
time point was measured in triplicate and the averages and standard deviations are
indicated.
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Figure 3.5. Release pattern followed by different cargo molecules
Human platelets (1.2×109 /mL) were prepared as described and were stimulated with
thrombin (0.3 U/mL) and the reaction was stopped with hirudin (0.6 U/mL) followed by
centrifugation. Releasates obtained at different time points were used to probe for the
moieties indicated using micro-ELISAs. Percent release was calculated using the equation
[(Releasate)/ (Pellet + Releasate)] x 100.
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Figure 3.6. Cargo release in response to different agonists
Human platelets (1.2×109 /mL) were prepared as described and were stimulated with
thrombin (0.3 U/mL, T; n = 3), convulxin (0.3 µg/mL, C; n = 2), PAR1-agonist (50 µM, P-1;
n = 2), or PAR4-agonist (500 µM, P-4; n = 2) for 5 min. Releasates were then probed
using the micro-ELISA arrays and the presence (gray square) or absence (white square)
of a given cargo molecule was recorded. Cumulative data indicates whether a cargo was
released at least once in any of the secretion trials performed with the indicated agonist.
Single donor indicates the cargo released by platelets from a single donor in response to
different agonists. PAR1/PAR4 indicates a direct comparison of the data for cargo
release in response to stimulation of either the PAR1 or the PAR4 receptor. Relative
abundance indicates the number of molecules of each cargo per resting platelet and was
measured using the micro-ELISA arrays.
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Figure 3.7. Rates of release of granule markers
Human platelets (3×108 /mL) were prepared as described. The rates of release of each
granule type when platelets were stimulated for 2 min with four different thrombin
doses (0.025 - 0.4 U/mL) were calculated [[3H]-serotonin for dense granules (red), PF4
for α-granules (blue) and β-hexosaminidase for lysosomes (green)]. Thrombin dose Vs
rate (Kex) graph was plotted.
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Figure 3.8. Fitting of the granule release data
The curves represent results of our measurements taken at t=0, 15, 30, 60, and 300 sec
and fit to equation 1 with MSE < 150 (A-D) and MSE < 250 (E and F). Panels A and B
show release curves with good fits (thrombin stimulated release of CD40L and MCP2,
respectively). Panels C and D release curves with fits closer to MSE = 150 (thrombin
stimulated release of GROα and angiogenin, respectively). Of 174 different granule
release measurements, 90 had MSE < 150. Panels E and F show release curves with fits
closer to MSE < 250 (PAR1-agonist stimulated release of IL-8 and PAR4-agonist
stimulated release of MCP3, respectively). Of 174 different granule release
measurements, 106 had MSE < 250.
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Figure 3.9. Kex values do not correlate with the molecular weights
The average Kex values for release of each cargo in response to stimulation with
thrombin (0.3 U/mL, A), convulxin (50 µg/mL, B), PAR1-agonist (50 µM, C), or PAR4agonist (500 µM, D) were plotted versus the molecular weights of the corresponding
cargo molecule. Linear regression analysis was used to determine if any correlations
exist between Kex and molecular weight. No R2 values reached significance.

66

Figure 3.10. Kex values do not correlate with the relative abundance
The average Kex values for release of each cargo in response to stimulation with
thrombin (0.3 U/mL, A), convulxin (50 µg/mL, B), PAR1-agonist (50 µM, C), or PAR4agonist (500 µM, D) were plotted versus the ranked order of abundance of the
corresponding cargo molecule. Linear regression analysis was used to determine if any
correlations exist between Kex and relative abundance. No R2 values reached
significance.

67

Figure 3.11. Kex values do not correlate with the relative charge
The average Kex values for release of each cargo in response to stimulation with
thrombin (0.3 U/mL, A), convulxin (50 µg/mL, B), PAR1-agonist (50 µM, C), or PAR4agonist (500 µM, D) were plotted versus the isoelectric points of the corresponding
cargo molecules (represented as relative charge). Linear regression analysis was used to
determine if any correlations exist between Kex and the isoelectric point. No R2 values
reached significance.
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Figure 3.12. Comparative pdf of Kex values from MSE, 150 and MSE < 250 datasets
Human platelets (1.2×109 /mL) were prepared as described and were stimulated with
thrombin (0.3 U/mL; n = 3), convulxin (0.3 µg/mL; n = 2), PAR1-agonist (50 µM; n = 2), or
PAR4-agonist (500 µM; n = 2) for increasing times. Releasates were probed using the
micro-ELISA arrays and the rate constant, Kex of release was calculated for each cargo
molecule. The pool of Kex values with MSE < 150 (top panel; 90/174) or MSE < 250
(bottom panel; 106/174) were used for constructing the pdf with a bin width of 0.0075.
The best fit curve is seen in black corresponding to the existence of three different subclasses. The dashed blue, green and red curves are the Gaussian functions that
represent fast, intermediate and slow classes, respectively.
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Figure 3.13. Distribution of Kex values
The rate constants Kex were calculated as described and the average was obtained for
each from multiple trials involving various agonists for stimulating the platelets. The
values are divided into three different classes represented by different colors based on
their distribution in pdf in Figure 3.12. The cargo in blue, green and red correspond to
the fast, intermediate and slow classes, respectively.
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Figure 3.14. Cargo characteristics from modeling operator variance
The distribution of the simulated Kex values (open symbols) assuming 3 (A, B, D) or 2 (C)
cargo classes with Kex values equaling the mean values obtained from the 3-Gaussian fit
shown in Figure 3.12 is shown. The closed symbols are the 90 Kex values obtained from
our experimental measurements. The Index is simply the ordinal number of the Kex
value. The rate constants and the operator variances used for the analysis are varied in
different panels to get a better overlap with the obtained experimental Kex values. The
description of the variable in each panel is: 3 cargo classes, Kex = 0.010, 0.067, 0.148, σop
= 0.2 (A); 3 cargo classes, Kex = 0.010, 0.033, 0.148, σop = 0.2 (B); 2 cargo classes, Kex =
0.010, 0.148, σop = 0.2 (C); 3 cargo classes, Kex = 0.010, 0.033, 0.148, σop = 0.1 (D).

71

Figure 3.15. Frequency distribution of Kex due to activation by different agonists
The rate constants Kex were calculated as in Methods. The gray bars represent the
frequency distribution of Kex values obtained upon stimulation of platelets with various
agonists as indicated. Superimposed dashed curves are the Gaussian functions shown in
Figure 3.12. The number of Kex values used in making the pdf incorporates 43 Kex values
for thrombin, 19 for PAR1-agonist and 17 for convulxin.
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Chapter Four
Involvement of SNARE Machinery in Determining Heterogeneity in Platelet Secretion
Introduction
The work described in the previous chapter suggested that platelet secretion was
more heterogeneous than originally thought. Our data demonstrated that platelet
secretion was in general not thematic, but was dependent on agonist dose and potency.
In the study of human platelets, our analysis was limited by the out-bred nature of our
donor pool and by the fact that the full array of secretory machinery was present. As
discussed in the Chapter One, platelets have at least two tiers of v-SNARE usage, the
primary tier that uses VAMP-8, and the secondary tier that employs VAMP-2/3. If
differential use of these v-SNAREs can affect release kinetics, then our analysis of human
platelets may miss subtle differences in cargo release dynamics. For this reason we
turned to a mouse platelet system in which there is a homogenous genetic background
and in which we can manipulate the levels of the individual v-SNAREs. In this chapter,
we describe the ground-work required for analysis of platelets from a number of VAMPdeficient mouse lines.
v-SNAREs, t-SNAREs, and a number of regulatory proteins determine the process
of platelet secretion by facilitating granule fusion. As described earlier in the Chapter
One, the minimal requirement for fusion to occur is the pairing of cognate v- and
heterodimeric/trimeric t-SNAREs to form a transmembrane fusion complex (Weber et
al., 1998). The goal of the work described in this chapter is to see if the v-SNARE
machinery in platelets contributes to any hidden pattern of platelet secretion. v-SNAREs
are type II membrane proteins with a 60-70 amino acid conserved SNARE motif (Jahn
and Südhof, 1999). Platelets contain VAMP-2 (synaptobrevin), VAMP-3 (cellubrevin),
VAMP-7, and VAMP-8 (endobrevin) (Bernstein and Whiteheart, 1999; Polgár et al., 2002;
Ren et al., 2007; Schraw et al., 2003). The neurotoxin, tetanus toxin, is an
endopeptidase, that specifically cleaves VAMP-1/2/3 (Schiavo et al., 2000). This toxin
was used in the early studies to determine the importance of v-SNAREs in platelets
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(Flaumenhaft et al., 1999). In a separate set of experiments an antibody directed against
the N-terminus of VAMP-3 (Feng et al., 2002) was used as an inhibitor. When either
toxin or antibody was added to streptolysin O permeabilized platelets, both agents
partially inhibited release (Flaumenhaft et al., 1999). These results were contradicted by
the lack of secretion defect in the platelets from VAMP-3-/- mice (Schraw et al., 2003).
Later studies showed a significant secretion defect in VAMP-8-/- platelets that could be
further reduced by treatment of permeabilized VAMP-8-/- platelets with tetanus toxin
(Ren et al., 2007). The conclusion drawn from these results suggested that VAMP-8 was
the primary v-SNARE since only its deletion caused a defect in release. VAMP-2/3 play a
secondary role and could facilitate release in VAMP-8’s absence, albeit less efficiently.
The fact that two v-SNARE-based systems could be functional in platelets led us
to question whether the two systems could mediate the release of different arrays of
granular cargo. For these studies, we sought to compare release from VAMP-8-/-, VAMP3-/-, and RC Tox :: PF4 Cre mouse platelets. The RC Tox :: PF4 Cre mice express the
tetanus toxin catalytic chain in response to the Platelet Factor 4 promoter-driven Cre
recombinase. Release from these platelets will be analyzed using the micro ELISA
scheme described in the Chapter Three. The work described here lays the foundation
for future work with these mouse strains.
Choice of agonists for the study
The agonists used in this study are thrombin, convulxin and PAR4, as in the
human study. PAR1-agonist was not included in the study as the mouse platelets have
PAR3/4 receptors. The experiments done so far entailed an initial agonist titration to
estimate the dose required for at least 80% secretion irrespective of the mouse-type
used for the study. Though the concept is to activate all the mouse platelets completely,
the secretion defect in VAMP-8-/- platelets was over-ridden by the increased agonist
concentration suggesting that any physiologically relevant secretion heterogeneity
pattern will be overwhelmed in this experimental paradigm. Future studies will require
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the use of lower doses of thrombin.

None-the-less, analysis of wild-type mouse

platelets was informative.
Release of cargo from wild type mouse platelets
Mouse platelets were isolated as described in the Chapter Two. An initial agonist
titration was performed for each agonist. The agonist dose that gave at least 80% of [3H]serotonin release was employed. The final concentrations of agonists used to stimulate
the platelets were 0.2 U/mL for thrombin (Figure 4.1, a), 0.5 µg/mL convulxin (Figure
4.1, b) and 400 µM for PAR4-agonist (Figure 4.1, c). The cargo molecules probed for are
listed in Table 4.1. The release profile over a time course of 5 min is indicated in Figure
4.1. As indicated in Table 4.2, potency of agonist determines the extent of release, as
was seen in the human platelets. The number of molecules released upon stimulation
with thrombin was 8, while it was 5 and 7 when convulxin or PAR4-agonist respectively.
Release of cargo from wild type and VAMP-8-/- platelets
Agonist titrations were performed before analyzing the releasates from the time
course experiments. The agonist doses that induced at least 80% of [3H]-serotonin
release are indicated in the Table 4.3. It was 0.2 U/mL of thrombin for wild type while
0.4 U/mL for VAMP-8-/- platelets. It should be noted that the dense granule release
deficiency from VAMP-8-/- platelets is overcome when stimulated with 0.5 U/mL
thrombin (Ren et al., 2007), therefore the higher levels of thrombin required for 80%
release was expected. This was also true when PAR4-agonist was used (Table 4.3). The
wild type platelets required 400 µM of PAR4-agonist while VAMP-8-/- platelets required
550 µM of PAR4-agonist for the same level of release. The rates of release of each
standard granule marker are also indicated in the Table 4.3. The release rates were
either less in VAMP-8-/- than in wild type platelets (dense and α-granule) or
approximately equal (lysosome) when stimulated with thrombin. The release rates of all
the three granules were almost the same between wild type and VAMP-8-/- platelets
when stimulated with PAR4-agonist.
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Discussion
The preliminary data obtained points towards the dependency of platelet
secretion on agonist-potency. The goal of this project is to see if the v-SNARE machinery
has any role in determining the phenotype of heterogeneity in the way platelets secrete.
The trials done so far involved the utilization of an agonist-dose that imparted 80%
dense granule release, irrespective of the agonist. As the goal was not to study
differential platelet activation and its impact on secretion, this strategy was chosen. But,
as any secretion deficiency due to the absence of v-SNARE (at least in VAMP-8 deficient
platelets) is overcome by high agonist doses, future studies to answer this question
would need to employ only minimal doses of agonist. Moreover, the choice of agonist
used will be restricted to thrombin, as the release can be controlled more tightly by
using hirudin to stop the release reactions. Cargo release will be further studied in
VAMP-8-/-, VAMP-3-/- and RC Tox :: PF4 Cre platelets as sufficient numbers of mice for
these studies become available. The knowledge gained from these preliminary studies
will help us guide this future analysis and to address whether v-SNARE usage contributes
to platelet secretion heterogeneity.

Copyright © Deepa Jonnalagadda 2013
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Table 4.1. Mouse array cargo

Growth
Factors

Symbol

Pro-Angiogenic

Cytokines/Chemokines

Anti-angiogenic

Cargo Name

EGF

Epidermal Growth Factor

SDF-1α

Stromal Derived Growth Factor - 1α

TPO

Thrombopoeitin

bFGF

Basic Fibroblast Growth Factor

VEGF

Vascular Endothelial Growth Factor

PF4

Platelet Factor 4

MMP2

Matrix Metalloproteinase -2

P-Selectin

P-Selectin

TGFβ

Transforming Growth Factor β

IL-1α

Interleukin - 1α

IL-1β

Interleukin - 1β

MIP-1α

Macrophage Inflammatory Protein - 1α

RANTES

Regulated upon Activation, normal T-cell expressed, and presumably
secreted

TARC

Thymus and Activation Regulated Chemokine

TNFα

Tumor Necrosis Factor α

Listed are the cargo molecules probed for on the micro-ELISA arrays. Their abbreviated
names (Symbol) are indicated in the middle column. The cargo molecules are grouped
according to their proposed functions (left-most column).
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Table 4.2. Rates of release from wild type mouse platelets

# detected

Thrombin

Kex

Convulxin

Kex

PAR4

Kex

bFGF

0.024

IL-1α

0.0043

EGF

0.0233

IL-1α

0.0320

IL-1β

0.0203

IL-1β

0.0299

IL-1β

0.0723

TARC

0.1081

MIP-1α

0.0774

TGFβ

0.0164 RANTES 0.0239

P-Selectin

0.0650

TNFα

0.0194

RANTES

MIP-1α 0.0343
TGFβ

0.0251

0.1738

TNFα

0.0269

TGFβ

0.0655

TPO

0.0253

TNFα

0.0496

8

5

7

Mouse platelets (4×108 /mL) were prepared as described and stimulated with thrombin
(0.2 U/mL), convulxin (0.5 µg/mL), or PAR4-agonist (400 µM) for 5 min. Releasates were
probed using micro-ELISA arrays to obtain the rate constant Kex for each cargo molecule
as described in the Chapter Two. The total number of molecules detected in the
releasate is represented in the last row.
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Table 4.3. Comparison of rates of release between wild type and VAMP-8-/- platelets
Kex values
Thrombin

PAR4-agonist

Wild type (0.2 U/mL)

VAMP8 -/- (0.4 U/mL)

Wild type (400µM)

VAMP8 -/- (550µM)

Dense granule

0.4368

0.2263

0.1101

0.1362

α- Granule

0.1295

0.05625

0.0136

0.03296

Lysosome

0.09316

0.09116

0.01937

0.02171

Mouse platelets (4×108 /mL) were prepared as described and stimulated with thrombin
and PAR4-agonist with the indicated concentrations over a span of 5 min. The rates of
release (Kex) were calculated for [3H]-serotonin release for dense granule, PF4 release for
α-granule and β-hexosaminidase release for lysosome as indicated.
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a

c

b

Figure 4.1. Release of cargo from the wild type mouse platelets
Wild type mouse platelets (4×108 /mL) were prepared as described and stimulated with
thrombin (a; 0.2 U/mL), convulxin (b; 0.5 µg/mL), or PAR4-agonist (c; 400 µM) for 5 min.
Releasates were probed using micro-ELISA arrays and the % release was calculated by
the equation (Amount in the supernatant / Amount released at 5 min) × 100. For
representing the data in the graphs, % release at 5 min point is set to 100% and the back
ground (release at 0 time point) was negated. The released cargo represented by
multicolored lines are listed adjacent to each panel.
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Chapter Five
Sphingosine-1-Phosphate in Platelets
Introduction
The bioactive lyso sphingolipid, Sphingosine-1-Phosphate (S1P) plays an essential
role in cellular metabolism (Spiegel and Milstien, 2003). S1P is essential for
development, growth, immune function, inflammation and cell migration. S1P has
gained further attention due its role in the formation of the vasculature. S1P is formed
by the action of sphingosine kinase (SK) on sphingosine. There are two isoforms of SK –
SK1 and SK2. Deletion of both the isoforms, in mice, is embryonic lethal (Mizugishi et al.,
2005). Of the two isoforms of S1P, a mouse expressing only one SK1 allele carrying a
myxovirus resistance 1–Cre was generated. These mice demonstrated the importance of
S1P in the maintenance of vascular integrity (Camerer et al., 2009) as S1P levels in
plasma are minimal. Erythrocytes restored normal plasma S1P levels in these mice and
thus vascular integrity. Plasma levels of S1P are very high (Hla, 2004) and are thought to
be maintained by endothelial cells, erythrocytes, platelets etc. None of the cell types
appear to be the only source of plasma S1P.
Platelets and erythrocytes are the hematopoietic reservoirs of S1P. Absence of
enzymes degrading S1P is responsible for the presence of ample amounts of S1P in
them. The release of S1P from RBCs is constitutive (Hänel et al., 2007). The interesting
characteristic that makes platelets stand out is that S1P is released only upon stimulation
(Yatomi et al., 1995). The mechanism of release of platelet S1P is unclear. Constitutive
and agonist stimulated release of S1P from mast cells (Mitra et al., 2006), and S1P
release in astrocytes (Sato et al., 2007) occurs through ABC transporters and the same
has been attributed to platelets. This is not supported by direct evidence. So the
mechanism of S1P release from platelets remains enigmatic. Endothelial cells are
recently reported to maintain normal plasma S1P levels (Hisano et al., 2012). Though
platelets may not be essential contributors to plasma S1P, their stores might become
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significant in modifying the microenvironment upon vascular injury. Localized release of
platelet S1P might help restore the vascular integrity.
The work described in this chapter attempts to address the mechanism of S1P
release from platelets. The presence of a carrier molecule, like bovine serum albumin
(BSA) was needed for detection of released S1P. This helped in the identification of a
BSA-extractable pool that was distinct from a potentially granular pool of S1P, which was
released upon platelet activation. This putative granular pool was not released from
secretion-deficient VAMP-8-/- and Unc13d Jinx mice platelets suggesting that the standard
exocytosis machinery was required for its release.

Consistently, a NBD-derivatized

Sphingosine (which was converted by platelets into NBD-S1P) was concentrated into a
granular organelle as determined by fluorescence microscopy. This observation was
further confirmed by sub-cellular fractionation studies. This is the first data to suggest
that there are two pools of S1P in platelets – agranular and granular.
Detection of released S1P from platelets is dependent on the presence of a carriermolecule in the media
We used mass spectrometry to measure released platelet S1P with an added
C17S1P as an internal standard for quantification. This approach enabled us to examine
the total platelet S1P and was a superior method to previously used radiolabeling
techniques which utilized [32PO4] that may misrepresent the importance of more
metabolically active pools of the lipid. Platelets contain significant amounts of S1P, but,
in our initial experiments there appeared to be very little that was releasable when
platelets were stimulated with thrombin (0.3 U/mL) (Figure 5.1a) or convulxin (0.3
µg/mL) (Figure 5.1b). Similar results were seen with mouse platelets. The secretion of
other granule components (PF4 and β-hexosaminidase) occurred normally. Given that
S1P is a lipid and may not be freely soluble once released, we included 1% fatty acid-free
bovine serum albumin (BSA) into the pH 7.4 HT buffer as a potential carrier or sink for
S1P. No S1P was found present in the preparations of Fraction V, fatty acid-free BSA
used throughout our studies (Table 5.1 and data not shown). Using this new buffer
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composition, release of S1P from either thrombin-stimulated (0.05 U/mL) human (Figure
5.2a) or mouse (Figure 5.2b) platelets could be readily detected. These data
demonstrate that S1P can be released from activated platelets but to detect it in the
supernatants of release reactions, a carrier, such as BSA, is required. All subsequent
experiments contained added BSA unless specifically noted. It is thought that the
hydrophobic binding sites on BSA serve as sink for the released S1P preventing it from
becoming integrated into the platelet plasma membrane. This enabled the direct
measure of released S1P in our assay system.
S1P levels in platelets and synthesis of S1P
One interesting feature of our data was the fact that the total levels of S1P in
human (Figure 5.3a) and mouse (Figure 5.3b) platelets increased with increasing BSA
concentrations. Even though the levels of human and mouse platelet S1P are different, a
ten-fold increase in BSA in the media caused only a two fold increase in endogenous S1P.
This suggested that new synthesis of S1P occurs in resting platelets when there is an
external sink for S1P. S1P stored in human platelets was 2.8±0.35 pmol/4×105 PLs and
0.139±0.007/pmol/4×105 PLs in mouse platelets. Since the platelet S1P levels increased
in the presence of a carrier molecule, we sought to determine if S1P was being
synthesized through the action of a platelet sphingosine kinase. Human platelets were
incubated with 6 µM C17 Sphingosine and the formation of C17 S1P was measured for
one hour. All the exogenously added sphingosine was converted to S1P within this
period. This indicates that sphingosine is converted into S1P rapidly and the enzyme
responsible for the conversion, sphingosine kinase is very active in platelets. The data for
C17 Sphingosine is not perfectly quantitative as D7 S1P (deuterium labeled) was
employed as an internal standard in its quantitation (Figure 5.4). Moreover, there was an
associated increase in the S1P levels released upon stimulation with increasing
concentrations of BSA (Figure 5.5).
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Levels of S1P in stored human platelets and platelet poor plasma
With an available sink in plasma (albumin/HDL) and active SK in platelets, the
extractable pool of S1P in platelets may be constantly turning over. To test this possibility
and its relevance in stored platelet rich plasma (PRP), the levels of S1P in platelets and
platelet poor plasma (PPP) were measured over time in a unit of platelets obtained from
the Kentucky Blood Center. For each measurement, PRP was removed from the unit bag
under sterile conditions and the bag was resealed. Over the time course measured,
there was a decrease in the amount of S1P stored in platelets; but there was not a
corresponding increase of S1P in the plasma (Figure 5.6a). This lack of change in the
plasma S1P level is most likely due to the overwhelming levels of S1P in plasma (almost
seven fold more) when compared to platelets. It is also possible that there was some
degradation of S1P in plasma since there was an initial decrease in the plasma S1P levels
that then leveled out (Figure 5.6b). The most overt loss of S1P was in platelets
suggesting that it is either released or extracted over time and the platelet’s ability to
synthesize new S1P is exhausted over the same time course.
Stimulation-dependent release of S1P from platelets
As is true for any platelet secretion process, the presence of calcium in the media
enhanced the release of S1P from platelets upon stimulation (Figure 5.7a). Release of
S1P from stimulated platelets depended on the agonist-potency. Weak agonist like ADP
released the least, while there was a dose-dependent increase in S1P release with
agonists like thrombin and convulxin (Figure 5.7b). The dependency of the platelet
release reaction on agonist potency has already been demonstrated for other granule
cargo (Chapter Three). Mouse platelets followed the same trend in the release of S1P.
This coincided with the release of a known α-granule cargo, PF4 (Figure 5.8a).
Time-dependent release of S1P from platelets
As the preliminary observations pointed towards a granular pool of S1P that
could be mobilized upon stimulation, we examined the time-course of its release.
Platelets were stimulated with thrombin for 15 sec – 5 min, and the released S1P levels
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were compared with a known platelet granule cargo, PF4 (Figure 5.8b). S1P and PF4
followed the same trend in their release time course.
The route of S1P release from platelets
The ABC transporter inhibitor, glibenclamide’s effects on S1P secretion
Glibenclamide, a sulfonylurea compound, was initially thought to inhibit ATP
dependent K+ channel (Fosset et al., 1988). It was later shown to be a general ABC
transporter inhibitor (Hamon et al., 1997; Haskó et al., 2002; McNicholas et al., 1996;
Payen et al., 2001; Schwanstecher et al., 1998). Previous studies with glibenclamide had
suggested the involvement of an ABC transporter in S1P export from platelets.
Specificity of this drug to inhibit S1P release from platelets was tested. Not only did
glibenclamide inhibit the release of S1P from platelets (Figure 5.9), but it also inhibited
dense granule release (Figure 5.10a), α-granule (Figure 5.10b) and lysosomal release
(Figure 5.10c). These release events are true secretion processes and no involvement of
an ABC transporter has ever been suggested. Therefore, these data would imply an offtarget effect of glibenclamide that affects platelet activation. Such results cast doubt on
the influence of glibenclamide on the release of S1P from platelets. Nevertheless the
effect of glibenclamide on S1P release was tested in the absence/presence of BSA. The
increased S1P release in the absence of BSA was surprising and unexplainable. As BSA is
essential for the detection of released S1P, the inhibition data in its presence is more
reliable. There was more than 20% reduction in the released S1P from platelets in the
presence of 200 µM glibenclamide. However, the same level of drug caused a ~55%
decrease in dense granule release (represented by detection of [3H]-serotonin, a 30%
reduction in PF4 release and a 19% reduction in β-hexosaminidase release. At this stage,
it is unclear exactly what effect glibenclamide has on platelets, but it is clear that it does
affect some aspect of platelet activation.
SNARE Machinery in S1P Secretion from Platelets
To test the involvement of the SNARE machinery in the release of S1P from
platelets, we utilized platelet secretion deficient mouse strains. Platelets from VAMP-8-/85

(V8-/-) and Munc 13-4-deficient, Unc13d

Jinx

mice were tested for the release of S1P.

Secretion of PF4 (Figure 5.11a) and S1P (Figure 5.11b) were analyzed. Secretion of S1P
from VAMP-8-/- and Unc13d Jinx mice when compared to the wild type mice was reduced
as was also seen for PF4 release (Figure 5.11). This provided convincing evidence for the
involvement of exocytotic machinery in the release of S1P from stimulated platelets.
Platelet secretion of S1P was reduced by 20% in VAMP-8-/- and 80% reduced in Unc13d
Jinx

mice when compared to wild type. The release of S1P was more severely affected in

Unc13d Jinx mice platelets than VAMP8-/-. Unc13d Jinx mice have a more robust defect in
dense granule release when compared to alpha granule release. The defect in S1P
release from the Unc13d Jinx platelets suggests that S1P may be released from the dense
granule compartment.
Comparison of amounts of S1P in secretion-deficient mice
The platelet S1P levels are 0.58±0.04, 0.3±0.01 and 0.38±0.04 pmol/4×105 PLs for
wild type, VAMP-8-/- and Unc13d

Jinx

mice respectively (Figure 5.12a). The plasma S1P

levels in human and mouse platelets do not differ much (3.76±0.63 pmol). There is a
slight increase in the amount of S1P found in VAMP-8-/- (4.61±0.48 pmol) and a decrease
in Unc13d

Jinx

(2.97±0.53 pmol) mouse plasma as indicated in Figure 5.12b. These

measurements are made per µL of platelet poor plasma left from the experiment
performed to look at platelet secretion as described in the previous section. The S1P
levels reported here are all in the presence of 1% fatty acid-free BSA. Though the
observed differences are statistically significant (p value < 0.05) there was no obvious
physiological significance.
Release of newly synthesized S1P
Given the apparent synthesis of S1P in platelets, we next wanted to see if the
newly synthesized S1P is exocytosed. To test this, C57BL/6 and Unc13d

Jinx

mouse

platelets were incubated with 2 µM C17 Sphingosine for increasing time followed by
stimulation with thrombin for 2 min. Though the levels of S1P detected (whether
endogenous [C18 S1P] or exogenous [C17 S1P]) in resting platelets was high, the
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percentage of S1P release was always less in Unc13d Jinx when compared to wild type
consistent with our previous results (Figure 5.13). To see whether newly synthesized S1P
was preferentially released (or not), fresh human platelets were treated with 6 µM C17
Sphingosine for 10 minutes and then stimulated for 5 minutes with two different doses
of thrombin. Low dose thrombin (0.05 U/mL) induced a small amount of S1P release
while higher thrombin (1 U/mL), induced more S1P release. This was true for both
endogenous (C18) and newly synthesized (C17) S1P (Figure 5.14). This observation was
made with several different batches of platelets and implies that the newly synthesized
pools of S1P are integrated into both granular and agranular stores.
Granular and agranular localization of S1P in platelets
Fluorescence microscopy
To confirm the granule residence of S1P in platelets, we resorted to fluorescence
microscopy. Platelets were incubated with fluorescently tagged sphingosine (NBDSphingosine). As sphingosine kinase is highly active in platelets, this label was expected
to be almost completely converted into NBD-S1P. This was tested by incubating banked
human platelets with 0.5 µM NBD-Sphingosine for 5-60 min to allow the synthesis of
NBD-S1P. At the indicated time points, the lipids were extracted and then separated by
thin layer chromatography. Within 10 min most of the NBD-Sphingosine was converted
to NBD-S1P. NBD-Sphingosine is unstable in platelets and is indicated by the top-most
bands (Figure 5.15a) which were thought to correspond to the cleaved NBD. Fresh
human platelets (Figure 5.15b) were labeled with mepacrine (A) and lyso tracker red (B).
Mepacrine is a green fluorescent dye used to label dense granules. Lyso tracker red is a
red fluorescent dye that localizes to acidic compartments such as lysosomes. Thus, they
serve as granule markers. This can be visualized in (C) where mepacrine and lyso tracker
red co-localize. Platelets were also labeled with NBD-Sphingosine (D) and the punctuate
appearance pointed towards granular localization. This was confirmed by co-localization
with lyso tracker red as seen in (F). Similar observation could be seen in the mouse
platelets (Figure 5.15c).
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Sub-cellular fractionation
The granule localization of S1P was further analyzed by sucrose gradient subcellular fractionation of platelets as described in methods. The fractions were analyzed
by western blotting for several compartment-specific marker proteins (Figure 5.16a):
αIIbβ3 for plasma membrane; Rab-GDI, for cytosol; VAMP-8 for granule membranes; PF4
for alpha granule cargo; and malate dehydrogenase for mitochondria. Concomitantly,
lipids were extracted from each fraction and were analyzed for S1P levels. There was a
gradual increase in S1P levels from fractions 2-5. This coincided with the trend followed
by the granule marker PF4. Fraction 1 in panel B included membrane composition along
with the cytosol due to our limited ability to separate two fractions and is responsible
for the observed abnormal high levels of S1P. Similar trend followed by VAMP-8 and S1P
in 2-5 fractions, confirmed our previous interpretation of granular pool of S1P. Taken
these data altogether, S1P was identified to constitute two pools - granular and
agranular pools.
Platelet S1P in determining vascular permeability
Given the defect in S1P release seen in the Unc13d

Jinx

mice, we sought to

determine if that defect affected vascular integrity by using the Evan’s blue dye assay. In
this assay, the Evan’s blue dye is injected, i.v. into an animal and after a period of time,
the animal is perfused and the lungs are removed. Blue dye in the lungs was quantified
as a metric of vascular leakage. A ratio of the dye OD to the total lung weight measures
the intactness of the vascular permeability barrier (Table 2) referred to as permeability
ratio. The permeability ratio was 1.34±0.20 for wild type mice (n=3) while that measured
for Unc13d Jinx mice was 1.43±1.02 (n=3). The vascular permeability barrier was defective
in one of the three Unc13d Jinx mice, but not in the other two (Table 2). While we show
no evidence that the released pool of platelet S1P contributes to vascular integrity, it
may play a role in certain circumstances. Further experiments with other secretion
deficient mouse lines may be needed to be analyzed in other assays of vascular
permeability that involve environmental stressors.
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Discussion
S1P was initially identified as a bioactive sphingolipid with an intracellular
signaling role. The discovery of S1P receptors on different cell types explained the
multifaceted roles of S1P - during development, formation of vasculature, in cell
migration and differentiation, inflammation, cell growth, cell proliferation etc. (Hannun
and Obeid, 2008). The spatial and temporal regulation of S1P determines cell fate. In
most cell types, S1P is produced only upon requirement. Plasma S1P levels are reported
to be maintained by platelets (Yang et al., 1999b), erythrocytes (Hänel et al., 2007) or
endothelial cells (Venkataraman et al., 2008) but, none of them have been confirmed to
be the sole source. Erythrocytes and platelets constitute the circulatory reservoir of S1P.
They accumulate S1P due to the absence of enzymes required for its degradation (S1P
lyase/phosphatase). While erythrocytes constitutively release S1P, platelets release S1P
upon stimulation (Yatomi et al., 2000). The mechanism of release of S1P from platelets is
unresolved. The work presented here demonstrates two pools of platelet S1P –
agranular and granular. Based on the obtained results, release of the granular pool
required the platelet secretory machinery.
S1P, in plasma, exists either bound to albumin or HDL particles (Okajima, 2002).
Our data suggests that, there is a requirement for a carrier molecule, like BSA, to detect
the release of S1P from platelets. Increased BSA availability in the media, increases S1P
levels both in human and mouse platelets. We interpret that the S1P level in platelets is
partially controlled by mass action. If there is a sink for S1P (i.e. BSA) then more is made
until the pool of substrates is exhausted. Perhaps it is this mechanism that explains the
platelets’ contribution to plasma S1P levels under “resting” conditions.
Previous reports suggested the involvement of ABCA1 like transporters to be
responsible for the release of S1P from stimulated platelets (Kobayashi et al., 2006).
Using a known ABC transporter inhibitor, glibenclamide, we showed that inhibition by
this compound may not be specific for S1P release. It also inhibited dense granule, αgranule and lysosomal release from platelets which indicates that the regulated release
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of S1P may not be solely transporter-mediated. Platelet secretion deficient mice
demonstrated the existence of a granular pool of S1P. VAMP-8-/- mice lack the primary
v-SNARE, VAMP-8 (Ren et al., 2007) while Unc13d Jinx mice are deficient in Munc13-4, a
regulatory molecule (Ren et al., 2010). Both proteins are required for normal platelet
secretion. S1P release from VAMP-8-/- and Unc13d Jinx mouse platelets was defective. As
the dense granule release defect is more pronounced in Unc13d Jinx mice, we speculate
that S1P may be stored in dense granules. The storage of S1P in dense granules can be
tested using HPS mice which lack dense granules. Some models have diminished levels
of dense granule cargo represented by limited population of dense granules, while some
have ghost dense granules. These empty dense granules can still be stained by
mepacrine, as there is no dysregulation in the uptake of contents. If S1P resides in dense
granule membrane, then HPS mice with ghost dense granules could be labeled with
NBD-S1P while those with no dense granules, might not incorporate NBD-S1P into
granules.
The absence or dysregulation of the SNARE machinery does affect the release of
platelet S1P. Whether this decreased S1P release affects the vascular permeability is still
unanswered. An initial attempt to address this question was made in the present study.
Secretion-deficient Unc13d

Jinx

mice had some leakage of the injected Evan’s blue dye

into the lungs indicating imperfect vascular permeability barrier when compared to the
wild type mice. As the data was not statistically significant, the role of platelet S1P in the
maintenance of vascular permeability has to be tested further. As the granular pool of
S1P is more likely to influence the local microenvironment upon vascular injury, it may
be more reasonable to assess the leakage of dye in the inflamed secretion-deficient
mouse model or in a model where the lesion is localized. It seems unlikely that there
will be global effect, especially given the fact that these mouse strains did not show any
large changes in plasma S1P levels.
Sphingomyelin degradation to form S1P is thought to happen in platelets (Tani et
al., 2005). With abundant sphingomyelin present in the membranes, there appears to be
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no need for platelets to have an external source of sphingosine or S1P. Though the
release aspect of platelet S1P is addressed by our work, the sub-platelet distribution of
S1P is still unclear. The fluorescent micrographs indicate the granular localization of S1P,
but such analysis focuses only on where the lipid is concentrated. As S1P cannot be by
itself, it either must be associated with some unknown protein in the platelets to exist in
cytosol or it has to be membrane-associated. If in the granule lumen, it is likely to be in
a complex with granular calcium salts.
The granular pool of S1P forms an easily accessible source to mediate localized
effect in the microenvironment upon vascular injury. Involvement of a transporter for
S1P export cannot be completely ruled out as the work presented here suggests only
one possible mechanism for the release of S1P. If a transporter mediates S1P export, its
availability on the surface might dictate S1P release. The granule membrane associated
transporters add onto the already available surface transporters upon granule fusion.
Thus, increase in transporter population might enable an increase in the probability of
S1P export and its extraction by a carrier-molecule like BSA. Identification of this
unknown receptor is still an open question.
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Table 5.1. Quality-check on fatty acid-free BSA

Sample #

C17 S1P (exogenous)

C 18 S1P (endogenous)

Blank

0.00E+00

0.00E+00

1

1.39E+05

0.00E+00

2

1.95E+05

0.00E+00

3

1.70E+05

0.00E+00

Liquid phase lipid extraction was done on pH 7.4 HT buffer treated with 1% fatty acidfree BSA and C17 S1P. Any association of S1P with the BSA was detected by MS analysis.
There was no detection of S1P in the blank sample that was not treated with any
exogenous S1P (C17) but with 1% fatty acid-free BSA. Samples #s 1, 2, 3 were treated
with exogenous S1P (C17). While that was detected, there was no detection of C18 S1P,
which is the endogenous S1P moiety that was measured for all the subsequent
experiments.
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Table 5.2. Permeabilization of lungs with Evan’s blue dye
Mouse type

OD

Lung weight (mg)

Permeability
(OD/Lung weight)

SD

Wild type

178.09

132.87

1.34

0.20

Jinx

221.32

156.73

1.43

1.02

Unc13d

Upon letting the indicated mouse strain to inhale isoflurane, 100µL of Evan’s blue dye
was injected into the jugular vein. The mice were allowed to stay calm for 15 min, and
were sacrificed later. After perfusion, the lungs were separated, dried and weighed.
Lungs were preserved in 1 mL of 1% paraformaldehyde. The intensity of the dye that got
into lungs was measured with odyssey IR scanner and permeability was calculated as
indicated in the table. The data is representative of the trials done on 3 mice each (SDStandard deviation).
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a

b

Figure 5.1. Release of S1P from platelets in the absence of carrier-molecule
Banked human platelets (2.5×108/mL) were resuspended in plain HT pH 7.4 buffer and
stimulated over time with 0.05 U/mL thrombin (a) and 0.3 µg/mL of convulxin (b). The
maximum time stimulated was 5 min. Granule cargo like PF4 was detected by ELISA and
β-hexosaminidase by an enzyme assay as described in methods. S1P was detected by MS
analysis upon extracting the lipids by liquid phase extraction detailed in methods. %
Release was assessed for the respective moieties by calculating (Amount detected in the
supernatant / Amount detected in supernatant + Pellet) × 100.
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a

b

Figure 5.2. Detection of secreted S1P from platelets in the presence of BSA
Washed human (a) and mouse (b) platelets (2.5×108 /mL) were prepared as described.
They were not stimulated (R=Resting) or stimulated with 0.05 U/mL thrombin for 45
seconds (S=Stimulated). Thrombin stimulation was stopped with 0.1 U/mL hirudin. The
samples were centrifuged at 13,000 × g for 2 min followed by separation of releasate
(supernatant) from platelets (pellet). This was done in the absence (-) or presence (+) of
1% fatty acid-free BSA. Lipids were then extracted as described in methods and detected
by mass spectrometry (MS). The supernatant and the pellet fractions constituted the
percentage release of S1P. The data are represented as the average ± SD, n = 3.
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a

b

Figure 5.3. Endogenous human and mouse platelet S1P levels
Washed human (a) and mouse (b) platelets (2.5×108 /mL) were prepared as described.
They were not stimulated or stimulated with 0.1 U/mL thrombin for 5 minutes and the
reaction was stopped with 0.2 U/mL hirudin. This was done in the presence of increasing
concentrations of fatty acid-free BSA as represented. Lipids were then extracted as
described in methods and detected by MS. The total amount of S1P in 4×105 platelets
has been calculated averaging the content in supernatant and pellet samples (no
difference was observed between them). The data are represented as the average ± SD,
n = 3.
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Figure 5.4. Synthesis of new S1P in platelets
Fresh human platelets (5×108/mL) were treated with 6 µM C17 Sphingosine over an hour
as indicated. The lipids were extracted at the end points as indicated. The amounts of C17
Sphingosine and C17 S1P were detected through MS. The data are represented as the
average ± SD, n = 3.
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Figure 5.5. Influence of BSA on release of S1P from platelets
Banked human platelets (2.5×108/mL) were resuspended in pH 7.4 Hepes Tyrode's buffer
without or with increasing concentrations of fatty acid-free BSA (0.05%, 0.1%, 0.5% and
1% respectively). Platelets were stimulated with 0.05U/mL of thrombin for 5 minutes.
The reaction was stopped by 0.1U/mL of hirudin. Platelets were then pelleted at 13,000
× g and the supernatant was separated. Lipids were extracted and S1P was detected by
MS. Percentage release of S1P was calculated. The data are representative of triplicate
samples (average ± SD, n = 3).
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a

b

Figure 5.6. Influence of storage on S1P levels in platelets and PPP
Washed platelets were prepared for a period of four consecutive days from the same
unit of PRP. Concomitantly PPP was saved from each preparation. Lipids were isolated
each time in triplicates from platelets and PPP. S1P was detected by MS analysis.
Amount of S1P was calculated as represented for platelets (a) and plasma (b). Each bar
represents an average of triplicate samples (average ± SD, n = 3).
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b

Figure 5.7. Release of S1P upon stimulation of platelets
Human platelets (2.5×108 /mL) were prepared as described in 1% fatty acid-free BSA and
with (+) or without (-) 1 mM Ca2+. The platelets were then allowed to sit at RT for 30 min
and 50 µL of them were stimulated with 0.05 U/mL thrombin for 5 min and stopped the
reaction with 0.1 U/mL hirudin (a). Fresh human platelets (5×108/mL) were treated as
before and stimulated with increasing concentrations of ADP, thrombin and convulxin as
indicated for 5 min at RT (b). All the samples were done in triplicates. Lipids were
extracted by liquid phase extraction and S1P was detected by MS analysis. % Release of
S1P was calculated and the data are represented as the average ± SD, n = 3.
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a

b

Figure 5.8. Platelet S1P release in a stimulation and time dependent manner
C57BL/6 mouse platelets (2.5×108 /mL) were isolated and resuspended in pH 7.4 HT
buffer with 1% BSA. Platelets were stimulated with increasing concentrations of
thrombin as indicated for 10 minutes at 37°C (a). Fresh human platelets (2.5×108/mL) in
1% fatty acid-free BSA were stimulated with 0.2 U/mL thrombin for indicated times and
the stimulation was stopped with 0.4 U/mL hirudin at the end of each time point at RT
(b). PF4 in both a and b was detected by ELISA. All the samples were done in triplicates.
Lipids were extracted by liquid phase extraction and S1P was detected by MS analysis. %
Release of S1P was calculated and the data are represented as the average ± SD, n = 3.
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Figure 5.9. Effect of glibenclamide on S1P secretion from platelets
Fresh human platelets (5×108/mL) with or without 1% fatty acid-free BSA were
incubated with or without 200 µM glibenclamide for 30 min and were then stimulated
with 0.5 U/mL thrombin for 2 min as indicated. The reaction was stopped with 1 U/mL
hirudin, platelets were separated by centrifuging the sample at 13,000 × g for 1 min and,
% release ([Amount in the releasate / Amount in the releasate + Pellet] × 100) was
calculated and plotted against time.
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a

b

c

Figure 5.10. Effect of glibenclamide on secretion of known platelet granule cargo
Fresh human platelets were isolated after incubating the platelet rich plasma with [3H]serotonin for 45 min. They were then treated with 200 µM (++) or 10 µM (+)
glibenclamide for 30 min and stimulated with 0.2 U/mL thrombin for 2 min. % Release of
serotonin was calculated interpreting [3H]-serotonin as a marker of dense granule
secretion (a). % Release of PF4 was calculated through ELISA as a marker of α-granule
secretion (b). % Release of β-hexosaminidase was calculated through an enzymatic assay
as a marker of lysosomal secretion (c). All the samples were done in triplicates and are
represented as the average ± SD, n = 3.
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a

b

Figure 5.11. Involvement of SNARE machinery in secretion of S1P from platelets
Mouse platelets (2.5×108 /mL) were isolated each from C57BL/6, VAMP 8-/- and Unc13d
Jinx

mice and were resuspended in 1% fatty acid-free BSA. They were stimulated with

0.05 U/mL thrombin for increasing amounts of time. The reaction was stopped with 0.1
U/mL hirudin and the platelets were separated from releasate by centrifuging at 13,000
× g for 2 min. All the samples were done in triplicates and the percentage release of PF4
at each point was determined by ELISA (a) and S1P was detected by MS (b). The data are
plotted as % release ([Amount in the releasate / Amount in the releasate + Pellet] × 100)
against time.
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b

Figure 5.12. Levels of S1P in secretion-deficient mice
Washed mouse platelets (2.5×108 /mL) were prepared each from C57BL/6, VAMP8-/- and
Unc13d

Jinx

mice and were resuspended in pH 7.4 HT buffer containing 1% fatty acid –

free BSA. They were stimulated with 0.05 U/mL thrombin for increasing amounts of
time. The reaction was stopped with 0.1 U/mL hirudin at the end of the time point. The
platelets were separated from releasate by centrifuging at 13,000 × g for 2 min. S1P in
the releasate and pellet was detected by MS after liquid phase lipid extraction. Total S1P
as represented in the graph (a) was calculated combining the S1P levels in the releasate
and pellet samples, and taking an average of all the samples included in the time course.
All the samples at each time point were done in triplicates and represented in the graphs
as average ± SD. The platelet poor plasma was separated from platelets by centrifuging
at 1700 rpm for 10 min from the indicated mice type and S1P levels were calculated
following the procedure as before (b). The data represented is an average of 7 samples
from each mouse type.
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Figure 5.13. Release of newly synthesized S1P from secretion-deficient mice
C57BL/6 and Unc13d

Jinx

were incubated with 2 µM C17 Sphingosine for different

amounts of time until 60 min as indicated in the graph for platelets to synthesize C17 S1P.
Following incubation they were stimulated with 0.05 U/mL thrombin for 2 min and
stopping the reaction by adding 0.1 U/mL hirudin. Platelets were then pelleted by
centrifuging at 13,000 × g for 1 min. S1P levels were detected and % release was
calculated as before.
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b

Figure 5.14. Agonist dose-dependent release of newly synthesized S1P
Fresh human platelets (5 × 108 / mL) were prepared and resuspended in pH 7.4 HT buffer
with 1% fatty acid-free BSA. They were incubated with 6 µM C17 Sphingosine for 10 min
and were later stimulated with either 0.05 U/mL (+) or 1U/mL (++) thrombin for 5 min.
The reaction was stopped with 0.1 U/mL and 2 U/mL hirudin respectively. Platelets were
pelleted by centrifuging the samples at 13,000 × g for 1 min. Lipids were extracted by
liquid phase extraction and, endogenous (C18) and exogenous (C17) S1P was calculated as
described before and the % release was obtained. The data are representative of 3
samples each (average ± SD).
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Figure 5.15. Localization of S1P in platelets
Banked human platelets (4.5×109/mL) in the presence of 1mM Ca2+ and 1% fatty acidfree BSA were incubated with 0.5 µM NBD-Sphingosine for 5, 10, 30 and 60 min as
indicated. Lipids were extracted by liquid phase extraction and loaded on a TLC plate as
described in methods (a). The first and the last lanes had NBD-Sphingosine and NBD-S1P
as controls respectively. Banked human platelets (5×108 /mL) were prepared as
described before and resuspended in pH 7.4 HT containing 1% fatty acid-free BSA (b).
They were incubated either with 1 µM mepacrine (A) and 1 µM lyso tracker red (B) OR
1µM NBD-Sphingosine (D) and 1µM lyso tracker red (E) for 30 min at 37°C. This was
followed by centrifuging the samples at 1600 rpm for 5 min and resuspension in fresh HT
buffer without BSA. About 10µL of the sample was put on a microscope slide and a cover
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slip was laid over. The slides were allowed to incubate for 30 min for the platelets to
settle down and viewed through 100X objective lens in oil immersion under Nikon
Eclipse 600. The same was performed for the wild type and Unc13d Jinx mouse platelets
(c).
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Figure 5.16. Sub-cellular fractionation of platelets
Human platelet homogenate was prepared as described in methods. Sucrose gradient
from 60% to 30% was prepared. Two milliliters of platelet homogenate obtained upon
nitrogen cavitation was overlaid. The fractions were separated by ultracentrifuging at
40,000 rpm at 4°C for 90 min, which were snap-frozen and stored overnight at -80°C.
The obtained fractions were concentrated by TCA precipitation and loaded on 12.5%
SDS-PAGE gel and analyzed for the indicated proteins by western blotting (a). The
corresponding fraction numbers are indicated above. S1P was detected by MS analysis
after liquid phase lipid extraction from the corresponding fractions (b).
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Chapter Six
Discussion
Part I - Existing view on platelet secretion
Platelets are presently recognized as the reservoirs of numerous proteinaceous
substances which appear to be mainly stored in α-granules. Since many of these cargo
molecules can affect different physiological processes, e.g. proliferation, angiogenesis,
inflammation, atherosclerosis etc., their roles may not be restricted to thrombosis. The
expanding boundaries of their participation underline the importance of understanding
the process of how they are released from platelets. The release pattern followed by
activated platelets is determined by the way they are packed. The cargo molecules can
be packaged into the α-granules either during platelet generation from megakaryocytes
(e.g. PF-4) or endocytosed during circulation (e.g. VEGF).
The importance of α-granule content release from activated platelets is best
demonstrated in GPS patients. Their platelets are characterized by numerous, giant,
ghost vacuoles representing empty α-granules. The proteins synthesized in
megakaryocytes, instead of being loaded into α-granules leak into the bone marrow
resulting in myelofibrosis (Nurden and Nurden, 2007). Though not life-threatening,
alarmingly variable symptoms are associated with this syndrome. The variability in the
extent of bruising seen in GPS patients confirms the importance of normal storage of
contents in α-granules. The defect has been recently identified to be localized to
chromosome 3p (Fabbro et al., 2011; Gunay-Aygun et al., 2010) and caused by a defect
in the NBEAL2 protein (Urban et al., 2012).
The distribution of platelet cargo in α-granules into distinct locations (Italiano et
al., 2008) and their secretion being dictated by the mode of platelet activation (Ma et
al., 2005) has raised a number of questions about platelet secretion. Are platelets
“smart bombs”, able to release thematically consistent cargo in response to specific
agonists or are they passive carriers that stochastically release their cargo in direct
correlation with their degree of stimulation? The work of Italiano et al. suggests that
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angiogenesis regulators can be packaged into distinct populations of α-granules.
Immuno-fluorescence and immuno-electron micrographs point towards distinct
localizations for pro- and anti-angiogenic factors (Italiano et al., 2008). Supporting these
studies, several groups (Chatterjee et al., 2011; Ma et al., 2005) have shown that
stimulating platelets with different agonists (i.e. PAR1- and PAR4-agonists) causes
differential release of some cargo. Pro-angiogenic factors have been proposed to be
released only upon stimulation with PAR1-agonist while anti-angiogenic factors are
released upon stimulation of platelets with PAR4-agonist. An alluring concept of platelet
secretion being contextually thematic was thus proposed. The flaws in these studies are
the focus on a narrow set of cargo molecules, limited set of agonist concentrations and
single time points used. Our data shows that partial activation contributes to the
perception of release heterogeneity (see Chapter Three). More recent work by Storrie
and colleagues has shown that cargo may be spatially segregated into sub-regions of the
same membrane-bound granule with minimal co-localization of factors with like
functions (Kamykowski et al., 2011; Sehgal and Storrie, 2007).

This would imply

stochastic packaging of cargo and perhaps some degree of homo-oligomerization similar
to what has been reported in chromaffin cells (Salazar et al., 2009). These views of
platelet secretion are conflicting and hence the need for the studies presented in this
dissertation. If there is heterogeneity in cargo packing and/or secretion as suggested,
regulating the release of specific α-granule sub-populations may allow specific
manipulation of the microenvironment at an injury site without disturbing hemostasis.
The work described here was an attempt to understand platelet secretion heterogeneity
and to overcome the drawbacks of the previous work. We used agonist concentrations
that yield maximal release responses and we examined the kinetics of release of a
significant number of platelet cargo molecules.
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Summary of the presented work
The secretion trends seen in the representative markers ([3H]-serotonin for dense
granules, PF4 for α-granules and β-hexosaminidase for lysosomes) provided an early clue
for the initial characterization of platelet secretion process. Also, the importance of
agonist-potency was obvious from the studies using thrombin titrations. The study was
broadened utilizing micro-ELISA chips to analyze 28 different cargo molecules. These
included pro- and anti-angiogenic factors, growth factors, inflammatory factors and
miscellaneous cytokines/chemokines. Release of these cargo molecules was
simultaneously measured upon stimulation of human platelets over a time-course of 5
min with different agonists (thrombin, PAR1/4-agonists, and convulxin). To avoid the
consequences of differential levels of activation, an initial agonist titration was done. An
agonist concentration yielding ~ 90% dense granule release was selected for further
analysis. Thrombin is a very potent agonist, which cleaves PAR1/4 exposing the tethered
ligand. To dissect the role of PAR1 and PAR4 activation individually, platelets were
stimulated directly with the respective peptides (SFLLRN for PAR1 and AYPGKF for PAR4).
To compare platelet secretion, stimulated through a different signaling pathway,
convulxin was employed as an agonist. It stimulates the platelets through GPVI pathway,
requiring tyrosine kinase activation. Hence, the choice of agonists used for the study was
designed to address the questions of extent of stimulation (thrombin vs. PAR1/4) and
mode of stimulation (thrombin vs. convulxin). Manual and mathematical analyses were
used to develop descriptors of the secretion process that could be used for comparisons
and analysis.
Agonist-potency determined the extent of platelet secretion. More cargo
molecules were detected in the releasate when the platelets were stimulated by a
potent agonist like thrombin; not as many were detected when platelets were
stimulated with less potent agonists, like PAR4. Evaluating the kinetic data by calculating
the rates of secretion (

and their probability density function (pdf) enabled us to

better understand platelet secretion. The distribution of cargo molecules into three
different kinetic classes identified in the pdf analysis was confirmed by the operator
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variance analysis. This approach takes into account inherent pipetting errors, cargopackaging, granule geometry, location of granule, mode of granule fusion - all factors
which contribute to the final observations. So many variables generate complexity in
data that cannot be entirely controlled. Operator variance analysis was included to
partially address this issue. Taken together, these analyses indicate that platelet cargo
release is distributed into three kinetic classes. The manual categorization of the
values combined with the statistical analyses (pdf and operator variance analyses)
directed towards the kinetic distribution of the platelet cargo into three classes – the
fast, intermediate and slow. There was no thematic pattern associated with the release
of cargo molecules. This was exemplified by the random distribution of angiogenic
factors

e.g. angiogenin, VEGF, angiostatin, and oncostatin M upon stimulation of

platelets with agonists differing in their potency. This was true for all the cargo
molecules selected for the study irrespective of their physiological activity. Several
factors leading to heterogeneity in platelet exocytosis are represented in Figure 6.1.
Our study minimized the heterogeneity in platelet secretion generated by partial
activation by using optimal doses of various agonists to ascertain same degree of
activation. Heterogeneity in platelet secretion detected in our experiments did not
follow any functionally relevant thematic pattern. Both qualitative and quantitative
analyses pointed towards the distribution of cargo molecules into three different kinetic
classes. This heterogeneity stems from diverse factors contributing to the complexity
seen in our kinetic analysis. An attempt to describe the need for heterogeneity in
secretion and some of the factors and multiple possibilities are described below.
Importance of existence of kinetic heterogeneity in secretion
Physiologically, the process of granule fusion is indispensable in synapses,
chromaffin cells, pancreatic β-cells, mast cells, etc. Some of these fusion events occur in
milliseconds, other in a few hundred seconds. The rate of fusion is thus controlled to
maintain normal physiology. Any deviation from the normal rates of fusion results in an
anomaly that could affect a number of processes. As described in Kasai et al. (Kasai et
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al., 2012), different cell types employ different rates of fusion, based on their
requirement. For example, the exocytotic rates in neurons fall in the range of few
milliseconds for expedite neurotransmission. The release of insulin from the pancreatic
β-cells is more sustained, and can take up to 600s to control the blood glucose levels.
The release events associated with several cell types have been categorized based on
the rates of fusion – ultrafast, fast and slow exocytosis events. Neurons stand out as the
exocytotic events of the synaptic vesicles can fall into all three categories. Based on our
work, platelets may be similar since platelet release rates can be categorized into three
kinetic classes. This sub-division, based on release rates, might be relevant for platelets
to carry on their functions, from the initiation phase in thrombus formation to the final
perpetuation phase. The sustained release exhibited by platelets becomes important in
regulating the microenvironment upon vascular injury.
The various possible contributors to the observed release kinetics are discussed
in the following sections: granule cargo packaging, geometry and location, and depicted
in the Figure 6.2.
Granule cargo packaging
The cargo could be packed distinctly in different α-granules (a). Even though αgranules outnumber dense granules and lysosomes, the hundreds of known cargo
proteins cannot be housed in <50 granules, a typical platelet contains. Therefore, this
strategy of individually designated granule cargo packaging is not plausible. The cargo
molecules are thought to exist as clusters and might be in the form of calcium-bound
aggregates. In this way, each granule could house cargo molecules of varying natures (b).
Moreover, there might be no restriction on the number of granule cargo molecules to be
housed by each granule. Such granule packaging may be satisfied by thematic
localization of cargo, cargo molecules with similar function (Italiano et al., 2008) (c) or
cargo with unrelated/contrasting functions to a distinct granule (Kamykowski et al.,
2011) (d).
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Granule geometry
Platelet α-granules are spherical in electron micrographs (e). For modeling the
kinetic data, we hypothesized granules to be spherical. Moreover, as the curvature of
vesicles determines the ease of fusion pore formation, a vesicle being spherical is more
accepted. More recent electron tomographic analysis suggests that granules are
elongated and tubular (van Nispen tot Pannerden et al., 2010) (f). The formation of
fusion pore is thought to be more efficient if the vesicle membrane has more curvature.
If the distribution of the cargo is homogeneous and the granule is spherical, then
irrespective of the granule fusion site, the rate of secretion should be uniform. If the
granule geometry is tubular (our data supports this hypothesis) and the distribution of
the cargo is more heterogeneous and clustered (analogous to the multi-colored candy in
a pixy-stick), the fusion site on the granule will determine the sequence of release of
cargo molecules and thus, their rates of release. Both Weibel Palade bodies (WPBs) of
endothelial cells and α-granules are reservoirs of vWF. WPBs are known to be tubular
(Huang et al., 2008). Through cryoelectron tomography and immuno EM, it has been
shown that α-granules are divided into at least, two sub-types, based on their
morphology – spherical and tubular (van Nispen tot Pannerden et al., 2010). While the
membrane proteins like αIIbβ3 and GLUT4 have been observed to be localized to tubular
sub-population, vWF and β-TG localized to the spherical granules. Fibrinogen was
distributed equally between spherical and tubular granules. As it was mentioned before,
WPBs, the stores of vWF are tubular; it is improbable that the content dictates the
geometry. But, a high spatial segregation is observed in these studies (van Nispen tot
Pannerden et al., 2010). Presence of both spherical and tubular α-granules adds to the
complexity of the release pattern.
Granule location
In addition to factors described above, an added feature that might contribute to
heterogeneity is the location of a granule. The way platelets are thought to exocytose
their contents is through the centralization of granules followed by fusion with OCS. As
introduced in Chapter One, OCS is the extra membranous system that is in continuity
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with the plasma membrane of the platelet. OCS serves as a route for secretion of
granule contents upon platelet activation (Escolar et al., 1989). If the granule is closer to
OCS or to the plasma membrane, the probability of exocytosing their content faster is
greater when compared to the granules away from the fusion site. Moreover, as
represented in Figure 6.2, the granules fusing with the plasma membrane can either be
spherical (g) or tubular (h). The shape of the granule might determine the
sequential/indiscriminate delivery of the granule contents to the exterior. The vicinity of
these granules to OCS/plasma membrane will determine the probability of granule
fusion.
One tier of the observed heterogeneity in granule secretion can be associated
with all the above described features. The second tier contributing to secretion
heterogeneity involves the mode of granule fusion. The multiple possibilities that might
determine the release rates are represented schematically in Figure 6.3 and are
discussed below.
The expedited fusion events are represented by the docked vesicles fusing with
the plasma membrane upon stimulation (a). They constitute the cargo molecules falling
in the fast kinetic class. Dense granules are already known to fall into this class, but there
is every possibility that an α-granule can also be a member of this class, though less
frequently. The release rates of several α-granule cargo molecules fall into the same
class as serotonin (a dense granule cargo) in our study. On the other extreme, most of
the granule cargo falls into the slow class. These events can be successful upon gradual
fusion of the undocked vesicles engaging in successful formation of SNARE complex and
finally fusing to release the contents (b). The third class of cargo release observed in the
pdf includes the intermediate class. The fusion events responsible for intermediate cargo
class in our kinetic analysis are represented in c and d. They represent bi-/multi-granule
fusion events respectively. Apart from the already docked vesicle fusing with the
membrane upon stimulation, this might be associated with the initial inter-granular
fusion followed by fusion with the vesicle already fused with the plasma membrane (c)
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and this ultimately can be represented by the final stage in (d) or can form a continuous
thread of vesicles releasing their contents through the vesicle that is fused to the plasma
membrane (d). This multigranular exocytosis is associated with the release of cargo in
bulk. As a result, the sequential release of cargo is more organized and restricted. This
would not prioritize cargo release based on their physiological function.
The mode by which the cargo molecules are released is most certainly a
combination of possibilities represented in Figures 6.2 and 6.3. Our initial analysis of the
granule fusion was built on the premise of spherical granules. Taking into account the
possible tubular geometry of a granule, the release events could be more organized
based on the original packaging. Moreover, a large number of cargo molecules are
represented in the slow class irrespective of the agonist used for stimulating the
platelets. Therefore, it is plausible that the release events represented by this class are a
combination of events depicted in Figure 6.3 b, c, d.
SNARE machinery constitutes the final contributor to the platelet secretion
heterogeneity. The following section in the discussion entails the contribution of SNARE
machinery.
Distribution of SNARE machinery
The role of SNARE machinery in driving granule fusion is depicted in the Figure
6.4. The minimal requirement for granule fusion to occur involves the participation of
cognate t- and v-SNAREs. Though true, the rate at which the fusion process proceeds in
vitro does not coincide with the rates of fusion in vivo demonstrating the importance of
a number of SNARE-regulators that control when and where the fusion complexes form,
and lead to a successful exocytotic event. The regulatory molecule, Munc 13-4 indicated
in 2 of Figure 6.4 drives granule fusion to completion. In the resting state, vesicles can
either be distal to their target membrane, undocked (1) or be proximal to the target
membrane, where the cognate v- and t-SNAREs have found each other, docked (2). The
regulatory molecule like Munc13-4 has been observed to anchor the cognate v- and tSNAREs in place aiding in the granule fusion process (Chicka et al, unpublished). If the
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granule is undocked, the release of cargo will be much slower since the time for the
movement of granule to the appropriate fusion site and for the cognate v- and t-SNAREs
to approach and recognize each other. On the other hand, if the granule is docked (2),
the cognate v- and t-SNAREs are already in place and are awaiting a trigger to proceed
with the granule fusion and release the cargo. These cargo molecules are associated
with faster release rates. A regulatory molecule, Munc 13-4 as already mentioned has
been observed to be involved in holding the docked vesicles intact (Chicka et al
unpublished). Stages 4, 5, and 6 represent possible explanations for the observed three
different kinetic classes of secretion in platelets. The underlying aspect in these stages is
the degree to which the SNARE machinery is employed. Loose, intermediate and the
tight stages of granule fusion explain the ranking of v- and t-SNAREs pairing in the
increasing order, signifying the ease of the fusion process to go to completion. In
neurons, calcium has been shown to act as a catalyst hastening fusion. The listed
exocytotic stages are categorized based on the proximity of v- and t-SNAREs to ascertain
a successful granule fusion event. The release rates of cargo molecules are dictated by
the stage of fusion that the granules are in. To be explicit, the cargo molecules stored in
a stage 5 granule are released faster when compared to those in stage 3. For the fusion
process to proceed from stages 3 to 5, the availability and continual participation of the
SNARE machinery is essential. This might involve recycling of SNAREs for maximal
availability. Not only is the position of granule relative to the target membrane
important in determining the fusion rate but also, the availability and prompt
participation of cognate SNAREs is important. The anchoring of t-SNAREs to the
membrane by acyl groups (Chen et al., 1999) points towards the possibility of t-SNAREs
to recycle enabling their increased availability to increase the granule fusion events. As it
is now understood that the release rates of the granule cargo are a function of granule
fusion process, controlling SNARE machinery determining the fusion rates has enhanced
significance. To our present knowledge, VAMP-8 is the primary platelet v-SNARE, while
VAMP-2/3 are considered to be the secondary v-SNAREs. Syntaxin-11 has recently been
identified as an important platelet t-SNARE. Selectivity of SNARE population to various
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granules is still an open question. To test the involvement of SNARE machinery in
determining platelet kinetic secretion heterogeneity, comparison of secretion kinetics of
VAMP-8 -/- and RC Tox :: PF4 Cre will be helpful. Moreover, subpopulations of α-granules
in the spreading platelets have been identified (Peters et al., 2012) to be associated with
distinct VAMPs. α-Granules employing VAMP-3 and VAMP-8 are more localized towards
the center of a spreading platelet while the granules employing VAMP-7 are
concentrated more towards the periphery. The differential utilization of SNARE
machinery thus might contribute to distinct kinetic classes in platelet secretion.
The observed platelet secretion heterogeneity is a combination of: granule cargo
packaging, granule geometry, granule location, modes of granule fusion and distribution
of SNARE machinery. Figure 6.1 is a schematic representation of all the described
features that could contribute to secretion heterogeneity. What was not explicitly
considered was the possibility that the granules are tubular. This is represented under
the ‘cargo release’ of Figure 6.1. Envisioning the extremity of the tubular granule fusing
with the membrane and resulting in sequential release of the cargo based on the order
in which they are packed is perhaps obvious. A ‘pixy-stick’ is a perfect analogy to
describe the process. The candy that is close to the opening comes out first while the
farther ones come out later sequentially. If the fusion does not involve the extremity of
the tubular granule, the release of the contents might follow a different release strategy.
The distribution of SNARE machinery therefore becomes very important factor in
determining the release rates.
A caveat to the work is that a cargo molecule stored in multiple granules cannot
be differentiated by the rate of release. The conclusion from the present study
represents only an average of several granules with similar cargo releasing their contents
following different patterns. The resultant signal is an average, representative of
heterogeneous release patterns as depicted in Figure 6.5. Whether or not the individual
platelet secretion of contents is sorted out, the resultant of the release of cargo
molecules in the microenvironment of vasculature/injury site is going to be the
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dominant character. Secretion in WPBs has been known to be time dependent and
selective (Babich et al., 2008). WPBs are heterogeneous, meaning have distinct granules
differing in their contents, and differential, meaning their release can be controlled
selectively by stimulation with distinct agonists (Cleator et al., 2006). We see that
platelet granules are heterogeneous in nature, but their release cannot be controlled
selectively. The difference in the assay methods employed as well as the endogenous
heterogeneity, as discussed, might contribute to the observed variability. Employment of
distinct SNAREs might attribute platelets to release their contents differentially.
Preliminary studies show that elimination of, secondary SNAREs (VAMP-2 and -3) or
VAMP-8, -2 and -3 selectively in mouse platelets had a diminished platelet secretion
(Joshi et al, unpublished). This demonstrates employment of distinct SNAREs dictating
variable fusion rates. Taken together, these analyses might indicate that VAMP-7 is
associated with granules localized to periphery in spreading platelets (faster Kex) and the
remaining identified SNAREs, VAMP-8, -2, -3, are associated with the centrally localized
granules (intermediate and slow Kex). Moreover this selective distribution of SNAREs
might not only determine fusion rates but also, if the cargo molecules released can be
effective in performing their physiological function based on the fusion site, more of
which will be discussed in the following section. The work presented here involves the
study of platelet secretion process, but does not address the influence of shear force in
circulation. None of the studies done so far involved the platelet secretion dynamics
under flow conditions. Employment of microfluidic devices (King and Diamond, 2012) in
the study of platelet secretion has a viable role in unveiling the granule characteristics in
platelets.
Importance of platelet secretion kinetic heterogeneity
Our data suggests that the platelets release their contents in three distinct
kinetic classes – fast, intermediate and slow. Serotonin was always associated with the
fast release kinetic class. Measurements could not be made in all the trials as the release
of serotonin was too fast for our analysis scheme. The remaining chemokines
irrespective of their function were distributed into all three kinetic pools; hence there
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was no detectable thematic pattern. Recent studies (Stalker et al., 2013) utilizing
confocal intravital microscopy have indicated hierarchical organization of the thrombus
at the site of vascular injury. The growing thrombus can be divided into a core region
and shell region (Figure 6.6). Upon vascular injury, platelets roll down the endothelial
lesion site, adhere, degranulate and recruit further more platelets. The core region
constitutes the most proximal region to the injury site. The core is characterized by
lower porosity with more fibrin and thrombin generation, and P-selectin exposure
indicative of α-granule release. The shell region is more distal to the site of injury and is
more porous and unstable. It is composed of platelets that are partially activated by
ADP and TxA2. Being small in size, molecules like ADP and TxA2 can extrude the core
region to activate platelets in the shell region. As the platelets in the shell region are
tethered and are partially activated, they are still capable of going back into circulation
blocking capillaries. Moreover, clopidogrel and cangrelor, which inhibit P2Y12 receptors
(receptors for ADP), reduced the size of shell region but not the core (Stalker et al.,
2013). This suggests that, manipulating the size of the shell region might prevent the
vascular occlusion that might lead to conditions like stroke and heart attack. Taken all
the observations together, kinetically segregated platelet secretion provides a layer to
regulation of microenvironment.
Our kinetic secretion data fits perfectly with this in vivo data (Stalker et al., 2013).
The cargo with fast and intermediate release kinetics might contribute to the formation
of the core region. It might result in faster wound healing if the constituents associated
with these release kinetics are growth factors and/or pro-angiogenic factors. The
contents that are slowly released might diffuse away with minimal localized effect. The
secondary agonists like ADP generated by platelets constituting the core region result in
activation of recruited platelets constituting the shell region. As thrombin production is
limited proximal to the injury site (core), platelets are likely to be activated by weak
agonists like ADP potentially decreasing the ability of platelets to completely
degranulate (shell). Therefore, the degranulation of platelets in distinct phases might
provide platelets the ability to stick to the lesion site, become active, recruit more
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platelets and the large number of molecules constituting the slow kinetic class might be
responsible for the modification/healing of the lesion site. The inflammatory molecules
discharged might limit the entry of infectious agents, the necrotic factors destroy the
damaged cells, growth and angiogenic factors help in the renewal of the damaged site.
Release of all molecules in bolus, might result in inefficient delivery of the required
factors at the right time. Those not essential for further platelet activation or
recruitment might drift away over time or those with short half-life lose their potency or
increased probability of encountering their inhibitors as they diffuse away. This provides
suitable explanation for the importance of existence of kinetic heterogeneity in platelet
secretion.
The results of the work presented here show that the granule cargo is
heterogeneous and there is no thematic pattern associated with the way they are
released. The significant feature that was detectable through our studies is differential
kinetic distribution of the cargo. Release of cargo over time as indicated by our studies is
beneficial in modifying the lesion site. The efficiency of the released cargo might as well
depend on the microenvironment it first sees after its release and thus spatial
orientation becomes an essential factor in deciding the fate of the released cargo. The
effect of cargo molecule accumulation would lead to pronounced localized effect if the
exit site of the cargo molecule of interest is towards the lesion site. If the exit site is
away, diagonal or opposite of the lesion site, the efficiency of the cargo molecule to act
is restricted and/or diminished. Release of contents in hierarchy following a thematic
pattern onto a lesion site cannot be addressed here as our secretion experiments are
conducted in suspension. Release of angiogenic and growth factors towards a lesion
surface might hasten modification of the damaged environment. Provision of a platform
for platelet secretion might accentuate the movement of the granules within a platelet
towards the surface (lesion site). This might result in increased probability of granule
fusion towards the lesion site thus increasing the chance of the released cargo to exhibit
its physiological function. The presence of a platform determining the directionality of
release events is yet to be tested. If there is a thematic pattern associated with platelets
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in releasing their contents upon activation, it coupled with detected kinetic
heterogeneity would add onto controlled platelet secretion. Though it is too early to say,
the above mentioned possibilities might entitle platelets to be called ‘smart bombs’.
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Part II - Distribution and movement of lipids
The asymmetric distribution of lipids across membrane bilayer is an important
determinant of cell metabolism. This is exemplified by the exposure of
phosphatidylserine (PS) on outer leaflet of plasma membrane in a dead cell. This
asymmetry is not only limited to the plasma membrane, but extends to cellular
organelles (Pomorski et al., 2004). The eukaryotic cell membranes are rich in
sphingolipids, cholesterol, and PS, whereas ER is depleted of these lipids. This is made
possible in a cell by a constant inward and outward diffusion of lipids. The spontaneous
movement of neutral lipids, like cholesterol; charged lipids like free fatty acids,
phosphatidic acid, phosphatidyl glycerol in their protonated form is fast (Hamilton,
2003). Lipids with polar head groups like PC, PS, PE, and glycolipids with large
carbohydrate moeities are considerably slower (Buton et al., 1996; McConnell and
Kornberg, 1971). To overcome this difficulty and maintain this dynamic equilibrium,
there are a number of supporting proteins (Bretscher, 1973). They can be energy
independent (e.g. scramblase) or dependent (e.g. translocases). Scramblases are
activated by calcium, usually associated with cell activation (as seen in platelets)
(Pomorski et al., 2001). The energy involvement in the maintenance of asymmetrical
distribution of lipids was first identified in erythrocyte membranes where PS from the
outer leaflet was incorporated into the cytosolic leaflet by unidirectional
aminophospholipid translocase (Middelkoop et al., 1989). This stands as an example for
inward translocation of lipids. The outward translocation of lipids was illustrated through
the studies involving multi drug resistance (MDR) proteins (Dekkers et al., 1998). These
are ATP binding cassette (ABC) family of proteins that extrude a variety of amphipathic
drugs from cells. Specific ABC transporters for transport of distinct lipids have been
identified. Selective maintenance of asymmetric distribution of lipids in cells is therefore
a highly controlled process.
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Bioactive lipids
The importance of bioactive lipids in various cell types is widely appreciated. This
is due to their involvement in regulating various cellular processes like cell growth,
survival, development, cell division, fusion of vesicles and intracellular signaling (Spiegel
and Milstien, 2003). Distinct lipids like phosphatidyl choline (PC) and free cholesterol
(FC) are dominant in different blood cell types. Platelets stand out because they have a
high amount of cholesterol esters when compared to other blood cells (Leidl et al.,
2008). More than two decades ago, the concept of ‘bioactive’ lipids emerged. Changes
in the levels of these lipids have biological implications highlighting the fact that lipids
are not merely passive cellular components and membrane constituents but do affect
cellular pathways and behavior. The involvement of lipids in the activation of PKC by
diacylglycerol (DAG) was demonstrated (Nishizuka, 1992). Eicosanoids, phosphatidyl
inositol 3,4,5 triphosphate (PIP3), phosphatidic acid (PA), lyso-phosphatidic acid (LPA) ,
platelet activating factor (PAF), sphingolipids, thromboxane A2 etc. form a list of
bioactive lipids that are relevant to platelets. Transport of these bioactive lipids is
essential to many functional responses.
The studies in Chapter Five focused on a bioactive lyso sphingolipid, Sphingosine1-Phosphate (S1P). The sphingolipid metabolism is complicated and is demonstrated by
the number of enzymes involved (e.g. 26 for ceramide) and the number of distinct
moieties of same compound grouped based on their desaturation, acyl chains and
hydroxylations (e.g. 50 distinct species for ceramide) (Hannun and Obeid, 2008). The site
of their generation and action often do not coincide. For example, S1P is generated on
the inner leaflet of the plasma membrane and can act by binding to its receptors
expressed on the cell surface. For this to happen, complex living systems developed
transporters and flippases. S1P transport is now known to be mediated by members of
ABC transporter superfamily (CFTR (Boujaoude et al., 2001), ABCC1 (Mitra et al., 2006)),
SPNS2 (Hisano et al., 2012). Flip-flop mechanism has been extensively studied in
ceramide transport. A ceramide transfer protein was identified which transports
ceramide from ER (site of synthesis) to the Golgi, where it is further metabolized into
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sphingomyelin (Hanada et al., 2003). Restricting the flip-flopping of these lipids does
impact their biological function (Marchesini and Hannun, 2004; Pomorski et al., 2004).
Transporters in platelets
Several transporters have been identified in platelets. Solute carriers (SLCs) and
ABC proteins have been identified to transport drugs, endogenous metabolites and
signaling molecules. The C – branch ABC proteins (Jedlitschky et al., 2004) (e.g. MRP4)
and A – branch ABC proteins (Albrecht and Viturro, 2007) play essential roles in the
maintenance of lipid homeostasis in platelets. Initially, ABCC4 [multidrug resistance
protein (MRP4)] was shown to be involved in pumping adenine nucleotides into dense
granules (Jedlitschky et al., 2004). MRP4 expression in platelets is on the dense granule
membrane as well as on the plasma membrane (Jedlitschky et al., 2004). Prostaglandins
(PGs) and thromboxane A2, initially thought to be passively transported, are now
identified to be actively transported by MRP4 in platelets (Tornhamre et al., 1998).
MRP4 is also identified to release cAMP and cGMP (Deeley et al., 2006; Jedlitschky et al.,
2004; Russel et al., 2008) which are the known intracellular second messengers to
maintain platelets in resting stage. Various transporters are therefore known to
contribute to platelet regulation.
Export of platelet S1P is important, as a bolus of S1P will be supplied on platelet
activation to modify the microenvironment. S1P is abundant in plasma, erythrocytes and
platelets. Platelet S1P pools become significant as they aid in localized effect upon
activation. The released platelet S1P is trapped at the growing thrombus in the vascular
injury site and not washed away by the shear flow of circulation. MK571, an inhibitor for
MRP1, also interfering with MRP4, blocked secretion of S1P from platelets (Ulrych et al.,
2011). S1P is also reported to be released via ABCA1-like transporter in platelets
(Kobayashi et al., 2006). Moreover, ABCA7 is identified in platelets and is expected to
play a role in the transport of S1P (Sasaki et al., 2003). None of the reports provided a
strong evidence for the transporter involved in platelet S1P transport.
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The work that is presented in Chapter Five addresses the route of S1P release from
platelets. The data suggested that there are two pools of S1P in platelets – agranular
and granular.
Summary of the presented work
Contrary to the instant turnover of S1P by the action of sphingosine kinase on
sphingosine seen in other cells, platelets store abundant amounts of S1P. This is possible
due to the absence of S1P lyase, the enzyme that results in its degradation. Mass
spectrometric detection of S1P secreted upon activation of platelets could only be
detected in the presence of a carrier-molecule like BSA, perhaps serving as a sink for the
bioactive lipid. Interestingly, with increasing BSA in the media, there was an increase in
total levels of S1P, in both resting and stimulated platelets. Synthesis of S1P from
sphingosine in platelets has been shown to be almost instantaneous due to the activity
of sphingosine kinase. The increased S1P in the presence of BSA might be consistent
with a mass-action effect in which BSA-extraction shifts the flux between S1P and
precursor pools and thus drives the synthesis of more S1P. This observation implies that
there is a readily-extractable pool of S1P in platelets that can partition into BSA’s
hydrophobic binding sites.
Release of S1P can also be measured in response to platelet activation. The
stimulation and time-dependent release of S1P from platelets was inhibited by
glibenclamide (ABC transporter inhibitor) as shown previously (Kobayashi et al., 2006).
However, glibenclamide also inhibited release of other platelet granule cargo suggesting
a non-specific affect of the inhibitor. The involvement of ABC transporters in the release
of S1P from platelets is therefore equivocal. Our studies are the first suggestion that
SNARE machinery is involved in the release of S1P from platelets. S1P release from
secretion-deficient mice, VAMP-8-/- and Unc13d

Jinx

mice was significantly affected.

VAMP-8-/- mice are deficient in a primary v-SNARE important for platelet secretion.
Unc13d Jinx mice are deficient in a regulatory molecule, Munc 13-4, important for platelet
secretion. Also, stimulation-dependent release of newly synthesized S1P was observed
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in platelets. The granular and agranular (BSA extractable) stores of S1P in platelets have
been confirmed through fluorescence microscopy and sub-cellular fractionation. The
importance of released platelet S1P in the maintenance of vascular permeability barrier
has been tested through Evan’s blue dye assay, with limited success as the data was not
statistically significant. Leakage of the injected dye into lungs was taken as a measure of
the strength of vascular permeability barrier. The contribution of platelet S1P in the
maintenance of vascular permeability barrier under inflamed conditions is much more
relevant. It can be tested in platelet secretion-deficient mouse model, Unc13d Jinx, upon
induction of inflammation by perhaps injecting an inflammatory agent like
lipopolysaccharide (LPS). This might be of significance as platelet granular pool of S1P is
more likely to play a physiological role upon vascular injury.
Mechanistic insights on the release of S1P from platelets
Subcellular localization of any bioactive sphingolipid is expected to affect the
efficiency of its signaling function. Based on their ionic charge and the associated
hydrophobicity, the bioactive lipid can/cannot voluntarily flip-flop across the membranes
(Hannun and Obeid, 2008). On the other hand, bioactive lipids like S1P, LPA, etc. due to
their amphipathic nature can move between the membranes. Restriction of distribution
of these bioactive lipids can limit their functionality (Pomorski et al., 2004).
The existence of agranular and granular pools of S1P in platelets has been
implied by the present study. The plasma membrane associated pools constitute
agranular pools of S1P while the granular membrane associated and the granular cytosol
distributed S1P constitute granular S1P pools in the platelets. The membrane localization
(whether granular membrane or plasma membrane) of S1P is understandable due to the
amphipathic nature of S1P. S1P in plasma is always seen associated with HDL or albumin,
and therefore its independent existence is unlikely. Either S1P has to be associated with
unknown carrier protein or should exist in an insoluble form in association with other
phosphate salts. The granular pool of S1P in platelets has been exposed utilizing the
platelet secretion-deficient mouse strains. As S1P secretion deficiency was more evident
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in Unc13d

Jinx

mice which have an absolute dense granule secretion deficiency, S1P is

thought to be stored in dense granules of platelets. If true, the defective release of S1P
might also be seen in patients with dense granule SPD (HPS). Some HPS mice have no
dense granules at all while some have membrane ghosts that actually could serve as
reservoirs for S1P if it was pumped into the granule.
Biological insights on the release of S1P from platelets
The activity of sphingosine kinase as well as S1P lyase/phosphatase and its
distribution has a significant impact on metabolic status of the cell as they control the
levels of S1P. S1P is known to be important for the maintenance of calcium homeostasis
(Ghosh et al., 1990; Ghosh et al., 1994). S1P by itself, independent of phospho lipase-C
can mobilize calcium stores (Mattie et al., 1994). It is known that calcium is sufficient for
activating platelets and allowing the SNAREs to mediate membrane fusion. S1P is stored
abundantly in platelets due to the absence of enzymes degrading it. The intracellular
calcium pools are encapsulated in dense tubular system in platelets and in the
mitochondria. To maintain the resting status of platelets, availability of S1P has to be
restricted. Hence it is essential to limit the movement of S1P in a resting platelet. The
idea of it being restricted to granules or associated with some unknown entity is
therefore viable.
S1P has been implicated in the regulation of cell migration essential for
embryonic development, organogenesis, wound healing and the immune response
(Spiegel and Milstien, 2003). S1P also plays an important role in angiogenesis(Lee et al.,
1999), vasculature formation, vascular permeability (Garcia et al., 2001) and vascular
maturation (Liu et al., 2000). These are possible through binding of S1P to S1P receptors
(S1P1-5) in various cell types. Spatial and temporal regulation of S1P therefore becomes
important. The ability of S1P in the maintenance of the microenvironment might
correspond to the diminishing concentration gradient of S1P from its central site of
production. The intracellular concentration of S1P is transiently high, unlike plasma,
erythrocytes and platelets that maintain huge levels of S1P. Out of all the abundant
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sources of S1P, plasma maintains the highest S1P levels. As already mentioned, S1P in
plasma exists bound to either HDL or albumin. Several sources of plasma S1P have been
reported which include, endothelial cells (Venkataraman et al., 2008), erythrocytes
(Hänel et al., 2007) and platelets (Yang et al., 1999a). Although different sources of
plasma S1P have their own significance, erythrocytes (Hänel et al., 2007) have been
found sufficient to maintain plasma S1P levels.
The data described here suggests two pools of S1P in platelets – agranular and
granular. If the release of S1P from any cell type is dependent on law of mass action, the
sink will be plasma due to the availability of ready carrier-proteins like HDL/albumin.
Erythrocytes are the circulatory reservoirs that release S1P into plasma constitutively
while platelets are known to release S1P only upon stimulation. Moreover no cell type
has been shown to be the sole supplier of S1P to plasma. This indicates that the S1P
stored in platelets is not to maintain plasma S1P levels. S1P stored in platelets might
become important at the site of injury. Platelets are activated naturally at the site of
injury and thus release S1P, whether granular or agranular. The released S1P from
platelets is susceptible to influence the micro-environment at the site of injury. The
therapeutic strategies aimed to diminish, but not completely abrogate platelet secretion
also would limit the availability of S1P at pathological damage site (e.g. plaque rupture).
This would in turn decrease the deployment of other immune cells and thus diminish
inflammation. Platelet S1P having any role in the maintenance of vascular permeability
is still questionable.
The conduit for the release of platelet S1P is still a gray area. The ABC inhibitors
used in the literature appear to be non-specific in platelets, and do not support ABC
transporters as candidates for releasing platelet S1P. SPNS2 has recently been found not
to be the S1P transporter on platelets but is for endothelial cells (Hisano et al., 2012).
The identification of S1P transporter on platelets is still unknown. The data presented
here suggests an increase in the availability of transporters required for S1P export on
platelet surface upon exocytosis. Platelets cannot synthesize S1P de novo. Sphingosine is
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thought to form through sphingomyelin degradation, and by the action of sphingosine
kinase on sphingosine, S1P is formed in platelets (Tani et al., 2005). With abundant
sphingomyelin present in the membranes, there appears to be no need for platelets to
have an external source of sphingosine or S1P. This might be one of the possibilities for a
continuous supply of S1P at the site of platelet activation, long after the exocytosis
event.
The work described here implies that there are two pools of S1P in platelets.
One that is BSA extractable in resting platelets, and one that requires the SNARE
machinery to get released upon activation (granular). The granular pool might be used
to give a bolus of S1P at the site of vascular damage so as to improve vascular integrity
at the site. Though plasma levels of S1P are high, the granular pool of S1P provides a
localized effect at the site of vascular injury. The S1P released from platelets is trapped in
the growing thrombus, and because it is not under the influence of shear flow, it is
retained at the site of release and is thus available to mediate localized effects.
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Figure 6.1. Schematic of release of contents from platelet
Endocytosed and megakaryocyte originated cargo are represented as multi-shaped and
circular structures respectively and are ultimately stored in α-granule. GPCR (G-protein
coupled receptor) represents one of the ways platelets are activated upon binding to an
agonist. Upon activation the inter-granule fusion and fusion of the granule with plasma
membrane leading to the release of contents is depicted as a sequential release dictated
by the granule fusion site and the granule geometry.
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OCS

Figure 6.2. Design of platelet granule determining the fusion rate
The cargo molecules can be packaged homogeneously as represented by multicolored
spherical granules (a) or each granule can be packed heterogeneously with similar
contents in multiple granules (b). This packaging can be in accordance with cargo
molecules of like functions (c) or with opposing functions (d). The granules can be
spherical (e) or tubular (f). Spherical (g) or tubular (h) vesicles can differ in vicinity to the
fusion site (OCS/plasma membrane).
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Figure 6.3. Different modes of granule fusion
The schematic presents the different modes of fusion. The arrows are directed towards
the post-stimulus stage. A pre-docked granule can result in simple expedited fusion (a).
A granule located in cytosol has to travel to site of fusion, post-stimulation (b). There
might be inter-granule fusion followed by fusion with already docked vesicle (c).
Sequential granule fusion (d) can result in release of cargo molecules from all the
granules involved in the fusion process with the fusion pore being maintained by the
initial vesicle.
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Figure 6.4. Influence of secretion machinery on granule fusion
Cognate v- and t-SNARE recognition ultimately leads to granule fusion upon platelet
activation whether undocked (1) or docked (2). Munc 13-4 has been observed to be a
regulatory molecule serving as an anchor to the docked vesicle for the fusion to reach
completion. The concept of the extent of v- and t-SNARE interaction ultimately leading
to the release of granule contents is depicted in 3, 4 and 5 described as loose,
intermediate and tight stages respectively. These stages represent the progression of
granule fusion upon platelet activation.
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Figure 6.5. Explanation of the caveat of the study
Only three platelets with limited granules are depicted to maintain simplicity. Each
platelet with a similar granule, differing in locales, can result in differential kinetics to
varying degrees when studied individually. With the strategy employed in the present
study, averages of multiple kinetic patterns is perceived as a final signal.
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Figure 6.6. Hierarchical organization of the growing thrombus
Under shear flow of blood, platelets in circulation start to adhere to the injury site,
undergo activation and release their contents. This forms the initial layer of platelets
(core) which further recruits more platelets to form the shell. The platelets constituting
shell are only tethered to the platelets in the ‘core’ and are hence, capable of returning
to the circulation. The secondary agonists from the ‘core’ might contribute to the
activation of platelets in the ‘shell’. The inset shows a zoomed picture of an activated
platelet depicting the granules as black dots. The black and the brown arrows represent
the release of the cargo stored in these granules away or towards a lesion site upon
fusion respectively.
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Figure 6.7. S1P in platelets
S1P exists in a granular pool and in an agranular pool. The agranular pool is extractable
by BSA alone. The granular pool requires the granules to fuse to the plasma membrane.
This might facilitate the exposure of S1P transporters present on granule membrane,
thus allowing further release of S1P.
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Abbreviations
(Ca2+)i
ABC
ARC
BEACH
BSS
C1P
cAMP
cGMP
CHS
CTAP
CTL
DAG
DNA
DTS
EDG
EGF
FGF
FHL
GP
GPCR
GPS
GRO
HDL
HGF
HPS
Hzf
IGF
IL
IP3
LAMP2
LDL
LPA
MIP
MK
MMP
Munc
MVB
MYH
NBEAL
NO
OCS

Intracellular Calcium
ATP Binding Casette
Arthrogryposis, Renal Dysfunction, and Cholestasis
Beige-Chediak/Higashi
Bernard Soulier Syndrome
Ceramide-1-Phosphate
Cyclic Adenosine Mono Phosphate
Cyclic Guanosine Mono Phosphate
Chediak Higashi Syndrome
Connective Tissue Activation Peptide
Cytotoxic T Lymphocyte
Di Acyl Glycerol
Deoxy Ribonucleic Acid
Dense Tubular System
Endothelial Differentiation Gene
Epidermal Growth Factor
Fibroblast Growth Factor
Familial Hemophagocytic Lymphohistiocytosis
Glycoprotein
G-Protein Coupled Receptor
Gray Platelet Syndrome
Growth Releated Oncogene
High Density Lipoprotein
Hepatocyte Growth Factor
Hermansky Pudlak Syndrome
Human Zinc Finger
Insulin like Growth Factor
Interleukin
Inositol 1,4,5 tris phosphate
Lysosome Associated Membrane Protein
Low Density Lipoprotein
Lyso-Phosphatidic Acid
Macrophage Inhibitory Protein
Megakaryocyte
Matrix Metallo Proteinase
Mouse Uncoordinated Mutants
Multi Vesicular Body
Myosin Heavy Chain
Neurobeachin-like 2
Nitric Oxide
Open Canalicular System
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PAR
PDGF
PF4

Protease Activated Receptor
Platelet Derived Growth Factor
Platelet Factor 4

PGI2
PSGL
RANTES
RBC
S1P

Protaglandin I2
P-Selectin Glycoprotein Ligand
Regulated and Normal T cell Expressed
Red Blood Cell
Sphingosine-1-Phosphate

S1P1-5
SDF
Sec1
SK
SNAP
SNARE
SPD
TIMP
TNF
TP
TSP

S1P Receptors 1-5
Stromal Derived Growth Factor
Secretion 1
Sphingosine Kinase
Synaptosomal Associated Protein
Soluble N-ethyl maleimide Associated Protein Receptor
Storage Pool Disorder
Tissue Inhibitor of MetalloProteinase
Tumor Necrosis Factor
Thrombopoeitin
Thrombospondin

TxA2
Unc
VAMP
VEGF
VPS33B
vWF
α-Granule
β-TG
δ-Granule

Thromboxane A2
Uncoordinated Mutants
Vesicle Associated Membrane Protein
Vascular Endothelial Growth Factor
Vacuolar Protein Sorting 33B
von Willebrand Factor
Alpha Granule
Beta-Thromboglobulin
Delta-Granule
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